

Exercise as medicine for depressive symptoms? A systematic review and meta-analysis with metaregression

Andreas Heissel , ¹ Darlene Heinen , ¹ Luisa Leonie Brokmeier , ¹ Nora Skarabis, ¹ Maria Kangas , ² Davy Vancampfort , ³ Brendon Stubbs , ⁴ Joseph Firth , 5 Philip B Ward , 6 Simon Rosenbaum , 7 Mats Hallgren , 8 Felipe Schuch • 9,10,11

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi. org/10.1136/bjsports-2022-106282).

For numbered affiliations see end of article.

Correspondence to

Dr Andreas Heissel, Sport and Health Sciences, Social and Preventive Medicine, Faculty of Human Sciences, University of Potsdam, 14476 Potsdam, Germany:

andreas.heissel@uni-potsdam.

Accepted 11 January 2023

ABSTRACT

Objective To estimate the efficacy of exercise on depressive symptoms compared with non-active control groups and to determine the moderating effects of exercise on depression and the presence of publication

Design Systematic review and meta-analysis with meta-regression.

Data sources The Cochrane Central Register of Controlled Trials, PubMed, MEDLINE, Embase, SPORTDiscus, PsycINFO, Scopus and Web of Science were searched without language restrictions from inception to 13 September 2022 (PROSPERO registration no CRD42020210651).

Eligibility criteria for selecting

studies Randomised controlled trials including participants aged 18 years or older with a diagnosis of major depressive disorder or those with depressive symptoms determined by validated screening measures scoring above the threshold value, investigating the effects of an exercise intervention (aerobic and/or resistance exercise) compared with a non-exercising control group.

Results Forty-one studies, comprising 2264 participants post intervention were included in the meta-analysis demonstrating large effects (standardised mean difference (SMD)=-0.946, 95% CI -1.18 to -0.71) favouring exercise interventions which corresponds to the number needed to treat (NNT)=2 (95% CI 1.68 to 2.59). Large effects were found in studies with individuals with major depressive disorder (SMD=-0.998, 95% CI -1.39 to -0.61, k=20), supervised exercise interventions (SMD=-1.026, 95% CI -1.28 to -0.77, k=40) and moderate effects when analyses were restricted to low risk of bias studies (SMD=-0.666, 95% CI -0.99 to -0.34, k=12, NNT=2.8 (95% CI 1.94 to 5.22)).

Conclusion Exercise is efficacious in treating depression and depressive symptoms and should be offered as an evidence-based treatment option focusing on supervised and group exercise with moderate intensity and aerobic exercise regimes. The small sample sizes of many trials and high heterogeneity in methods should be considered when interpreting the results.

Check for updates

permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

@ Author(s) (or their

employer(s)) 2023. Re-use

To cite: Heissel A. Heinen D. Brokmeier LL, et al. Br J Sports Med Epub ahead of print: [please include Day Month Year]. doi:10.1136/ bjsports-2022-106282

INTRODUCTION

Depression is a prevalent and disabling disorder associated with reduced quality of life, medical comorbidity and mortality. 1 2 Over 300 million

WHAT IS ALREADY KNOWN?

- ⇒ Depression is the leading cause of disability worldwide with potentially increasing prevalence since the COVID-19 pandemic, vet more than two thirds of adults diagnosed with depression remain untreated.
- ⇒ Exercise is an efficacious treatment option for reducing depressive symptoms for individuals with depression.
- ⇒ However, evidence reported by meta-analyses reveals heterogeneous effects and is not up to date.

WHAT ARE THE NEW FINDINGS?

- ⇒ This methodologically sound systematic review and meta-analysis with meta-regression is the largest synthesis of the effect of exercise on major depressive disorder (MDD) and depressive symptoms covering 41 included studies, accounting for 2.264 adult participants postintervention.
- ⇒ Results show moderate to large effects of exercise on depressive symptoms even when limiting the analysis to low risk of bias studies or only MDD, although high heterogeneity among the studies was addressed with meta-regression.
- ⇒ Non-inferiority trials indicate that exercise is non-inferior to current first line treatments, and evidence that exercise is effective at long-term follow-ups are needed to clarify the identified evidence gaps.

people live with depressive disorder, equating to approximately 4.4% of the world's population.3 The prevalence of depression has increased during the COVID-19 pandemic⁴⁻⁷ by an estimated 27.6%, highlighting the need for appropriate, accessible and cost-effective treatment options.8

Currently, recommended treatments include psychotherapy and antidepressant medication (or a combination of both). However, psychotherapy achieves remission rates of only 50% while typically being cost-intensive. 10 Side effects and relapses from antidepressant medication commonly occur¹¹ as can withdrawal symptoms. 12 Importantly, about two thirds of adults with depression do not receive adequate treatment.¹³ Untreated depression often





Review

leads to intensification of the illness including the development of comorbidities resulting in even higher costs for society. ¹⁴ This attests to the need for rapid and readily available alternative treatment options.

Exercise has been recommended as an adjunct treatment for depression by both the WHO¹⁵ and National Institute for Health and Care Excellence (NICE) guidelines.¹⁶ Evidence for these recommendations included results from multiple meta-analyses investigating the antidepressant effect of exercise in people with depression. ^{17–20} However, some of these meta-analyses ¹⁸ ²¹ found moderate, weak or no effects of exercise while others reported large effects. ¹⁷ ¹⁹ ²⁰ These mixed results stem from methodological and conceptual differences regarding inclusion criteria and analytical approaches. For example, some studies focused on individuals with a diagnosis of major depressive disorder (MDD) while excluding studies that evaluated the presence of depression based on validated screening measures. 18 Others 17 investigated the effect of exercise alone or as a complementary treatment for depression to pharmacological therapy for studies published from 2003 to 2019. Further, some reviews included studies where patients also received exercise interventions²¹ in the control groups. This creates the potential for bias²² as even light intensity exercise can exert antidepressant effects. Importantly, a cause for concern has been raised in several reviews that exercise does not have a significant effect when restricted to 'low risk of bias' randomised controlled trials (RCTs). 18 21 Therefore, extant meta-analyses have failed to provide convincing evidence to enable clinicians globally to implement exercise as an evidence-based effective treatment option for depression. One meta-analysis²⁰ addressed these methodological shortcomings by focusing on studies that included samples with depression using cut-offs on validated screening instruments and samples with MDD diagnosis assessed with diagnostic tools and including only studies that compared exercise versus non-active controls. The authors excluded trials comparing different exercise regimens. However, a large volume of studies has been published within the last 5 years, requiring an updated meta-analysis on the antidepressant effects of exercise, while addressing the shortcomings of previous reviews.

The objective of this meta-analysis was to update the current evidence on the effects of exercise in reducing depressive symptoms in adults with clinically elevated levels of depression including MDD and dysthymia, comparing exercise with non-exercising control groups. Additionally, we aimed to investigate the potential moderators of the antidepressant effects of exercise, and the presence of publication bias.

METHODS

Search strategy and selection criteria

This systematic review and meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with the protocol number CRD42020210651. The PRISMA Statement was followed²³ in its updated version²⁴ additionally considering the PERSiST guidance (implementing PRISMA in Exercise, Rehabilitation, Sport medicine and SporTs science).²⁵

To structure the eligibility criteria, the PICOS (Patient/Population; Intervention; Comparison, Outcome; Study design) approach was used. Eligible for this meta-analysis included studies that: (1) Investigated participants aged 18 years or older with a primary diagnosis of MDD or dysthymia defined by the Research Diagnostic Criteria, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV or DSM-5)²⁷ or

International Classification of Diseases (ICD-10)²⁸ or adults with depressive symptoms determined by validated screening measures scoring above the threshold value (eg, Beck Depression Inventory (BDI) or Hamilton Rating Scale for Depression (HAM-D)). ^{29 30} If scales did not have validated cut-offs, the cutoff used by the author was accepted. (2) Investigated an exercise intervention in the treatment of depression, where exercise was defined as planned, structured, repetitive and purposive physical activity with the purpose to improve or maintain physical fitness.³¹ Studies using yoga, tai chi or other mind-body activities were excluded, because the focus of such mind-body interventions are behavioural techniques that include, but not limited to, deep breathing, meditation/mindfulness and self-awareness.³² (3) Included a non-exercising control group, such as usualcare, wait-list control conditions or placebo pills. Studies with any other exercise intervention (such as stretching or low-dose exercise) as a comparator were excluded as well as control and intervention groups commencing standardised interventions (eg, psychotherapy, medication) at the beginning of the intervention even if this was applied to both intervention and control groups (eg, starting medication treatment at the beginning of the intervention in both groups). However, ongoing treatments started at least 3 months before intervention initiation were included. (4) Examined the pre-post effects of exercise interventions on depressive symptoms using a validated depression scale. (5) Were RCTs and were published in peer-reviewed journals or as part of a dissertation. Conference proceedings were not included.

An electronic search of the following databases was conducted: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE, Embase, SPORTDiscus and PsycINFO without any (eg, language or date) restrictions from inception to 13 September 2022. The search used a range of relevant terms to capture all potentially eligible results relating to exercise interventions for depressive symptoms (for the full list of search terms, see online supplemental text 1). Duplicate references were removed electronically and manually. To identify unpublished or ongoing studies, clinical trials.gov (www.clinicaltrials. gov) was searched. Additionally, reference lists of all eligible articles of recent reviews investigating the effectiveness of exercise versus control were screened to identify potentially eligible articles. All manuscripts were reviewed by at least two independent reviewers. Three reviewers (NS/LLB, DH) independently determined potentially eligible articles meeting the inclusion criteria using the titles and abstracts. Three independent reviewers (NS/ LLB, DH) then applied the eligibility criteria after obtaining the full texts and generated a final list of included articles through consensus. If full-texts were not available, study authors were contacted to provide them. Five investigators (NS/ LLB, DH, FS, AH) judged article eligibility with any disagreements resolved through discussion.

Data extraction

Data extraction was done by three reviewers (NS/ LLB, DH) independently. A systematic extraction form was used for each article to collect the following data: (1) sample description (eg, sample size, mean age of participants); (2) intervention features (eg, type of exercise, length of trial); (3) methodological factors (eg, risk of bias, instruments used for diagnosis and symptom assessment); (4) effects on depressive symptoms (eg, changes in total depressive symptoms scored before and after intervention). For further information of extracted data see online supplemental tables 1, 4 and 5.

Primary outcome

The primary outcome was the mean change in depressive symptoms in the exercise compared with the control group from baseline to postintervention. The primary outcome proposed by the authors was selected if two or more instruments were used.

Study quality assessment

Selected studies were assessed by three independent authors (NS/LLB, DH) given an overall estimation of risk of bias (ie, low risk, some concerns or high risk) according to the revised Cochrane risk-of-bias tool for randomised trials (RoB2).³³ According to RoB2, the following domains were considered for the assessment of risk of bias: randomisation process, deviations from intended interventions, missing outcome data, measurement of the outcome and selection of the reported result (see online supplemental table 3).

Data-analysis

A random effects meta-analysis was calculated due to expected heterogeneity. The standardised mean difference (SMD) and 95% CIs were used as the effect size (ES) measure. The SMD was calculated using the difference from pre to post intervention³⁴ with correlations of 0.7 between the exercise and the control group. All results were calculated on an intention-to-treat basis. Heterogeneity was calculated using the I^{2,35} Sensitivity analyses with pre-post-correlations of 0.6 and 0.8 were calculated to investigate changes in effect with less or more conservative values. Sensitivity analyses were further calculated excluding one study due to unequal distribution of psychotherapy among the intervention and control group and excluding studies with high risk for bias. Potential moderators (see table 1) of the antidepressant effects of exercise were investigated using linear meta-regression analyses for all studies and, separately, for studies including only patients with a diagnosis of MDD and/ or dysthymia. Meta-regression assumptions were tested in JASP. Subgroup analyses were calculated to estimate the effect across depression classification, risk of bias, differing control conditions, intensity of exercise, exercise type, exercising in a group or individually, sample sizes and supervision (by different supervisors). We also calculated the mean difference (MD) on studies that assessed depressive symptoms using the Hamilton scale for depression or the BDI separately. Significance level was set at 0.05.36 Publication bias was assessed with visual inspection of funnel plots and with the Begg-Mazumdar Kendall's tau³⁷ and Egger bias test.³⁸ Whenever significant, the Duval and Tweedie Trim and Fill was applied.³⁹ Fail safe number of negative studies that would be required to nullify (ie, make p>0.05) the ES were calculated.⁴⁰ All analyses were performed using Comprehensive Meta-Analysis software, ³⁸ and number needed to treat (NNT)⁴¹ analyses were calculated using Lenhard and Lenhard⁴² with the formula of converting Cohens' d to NNT from Furukawa and Leucht. 43 Additionally, studies reporting (severe) adverse events and side effects were listed.

RESULTS

Search results

Searching of databases yielded 15 734 studies and an additional 84 studies were identified through other sources. Following removal of duplicates, 7100 potentially eligible studies remained for which abstracts were screened. At full text stage, 207 studies were reviewed and 166 removed because they failed to meet inclusion criteria (see online supplemental table 2 for references

and exclusion reasons). The remaining 41 studies were included in the review and quantitative synthesis (see figure 1).

Study characteristics

In total, 2544 participants are included in the review and 2264 completed treatments (post-treatment n) and were included in the meta-analytical calculations, 1227 in intervention groups and 1037 in control groups. Twenty-one studies assessed depressive symptoms, ⁴⁴⁻⁶⁴ while MDD was diagnosed in 20 studies. ⁶⁵⁻⁸⁴ Percentage of females ranged from 26% to 100%, mean age from 18.8 to 87.9 years. Of the 41 included RCTs, studies originated from North and South America, Europe, Asia and Australia. See online supplemental table 1 for characteristics of selected studies (further characteristics are summarised in online supplemental tables 4 and 5).

Risk of bias

Risk of bias assessment revealed 12 studies to be rated of low risk of bias, $^{49\,58\,60\,65\,66\,68-70\,74\,79\,80\,82}$ while 7 were rated with some concerns. $^{44\,45\,48\,51\,55\,73\,76}$ For 22 studies, RoB2 indicated high risk for bias. $^{46\,47\,50\,52-54\,56\,57\,59\,61-64\,67\,71\,72\,75\,77\,78\,81\,83\,84}$ For full details, see online supplemental table 3.

Main analysis

The main analysis of pooled data from 41 studies showed a large effect favouring exercise for a pre-post-correlation of 0.7 (SMD=-0.946, 95% CI -1.18 to -0.71, p<0.001, I^2 =82.49, p<0.001; see figure 2). Publication bias was indicated by Begg-Mazumdar Kendall's Tau^{37} (= -0.379, p < 0.001 and the Egger³⁸ tests (intercept = -2.706, p < 0.001). However, Duval and Tweedies' trim and fill method did not affect the effect. Fail-safe number of additional negative studies was 2789. The visual inspection of the funnel plot (see online supplemental figure 1) did not indicate risk of bias. Sensitivity analyses revealed a trivial change in the effect from -0.930 (95% CI -1.16 to -0.70, p<0.001, I²=82.032, p<0.001) for a 0.8 pre-post-correlation to -0.957 (95% CI -1.19 to -0.72, p<0.001, $I^2=82.820$, p<0.001) for a 0.6 pre-post-correlation. Excluding one study⁷⁴ due to unequal distribution of psychotherapy treatments among the intervention and control group (20% vs 0%, respectively) revealed an effect of SMD=-0.938 (95% CI -1.17 to -0.70, p<0.001, I^2 =82.703, p<0.001). Excluding studies with high risk of bias (see online supplemental table 3) rendered a moderate effect favouring exercise intervention (SMD=-0.717, 95% CI -1.01 to -0.43, p<0.001, I^2 =82.372, p<0.001). Excluding studies with less than 6 weeks of intervention (see online supplemental table 1) showed a large effect favouring exercise intervention (SMD=-0.959, 95% CI -1.21 to -0.71, p<0.001, $I^2=84.132$, p<0.001). I^2 is suggesting substantial heterogeneity for the analyses.

Subgroup analyses

Subgroup analyses (summarised in table 1) showed that the beneficial effect of exercise on depression remained for all subgroups regarding depression classification, risk of bias, group exercise, the sample size of the trial and supervision by exercise professionals. Aerobic (SMD=-1.156) and resistance training (-1.042) as exercise types showed large effects whereas mixed aerobic and resistance training showed small effects (-0.455). Large effects were also found for studies including sample sizes in the intervention arm of less than 25 participants (SMD=-0.868 to -1.281) whereas larger samples of participants revealed moderate effects (SMD=-0.532).

		Meta-analy	rsis			Heterogeneity	Trim and fill effect size (95% CI) (adjuste		
Analysis	Number of RCTs	SMD	95% CI		P value		studies)		
Main analysis	41	-0.946	-1.18	-0.71	<0.001	82.490	Unchanged		
Depression classification							· · · · · · · · · · · · · · · · · · ·		
MDD*	20	-0.998	-1.39	-0.61	<0.001	84.746	-1.167 (-1.59 to -0.74)(2)		
Depressive symptoms	21	-0.915	-1.21	-0.62	<0.001	78.974	Unchanged		
Risk of bias									
Low risk of bias	12	-0.666	-0.99	-0.34	<0.001	80.218	-0.367 (-0.72 to -0.01) (4, right of mean)		
Some concerns	7	-0.829	-1.49	-0.16	0.015	86.926	-1.151 (-1.86 to -0.45) (2)		
High risk of bias	22	-1.199	-1.59	-0.81	<0.001	81.484	Unchanged		
Type of control condition									
Usual care	22	-0.949	-1.25	-0.65	<0.001	82.951	Unchanged		
Wait list	11	-1.238	-1.69	-0.79	<0.001	73.749	-1.008 (-1.43 to -0.59) (3, right of mean)		
Health education	3	-1.123	-2.56	0.31	0.125	93.955	Unchanged		
Intensity of exercise†									
Light	2	-1.041	-2.53	0.45	0.170	88.867	N/A		
Moderate	26	-1.132	-1.45	-0.81	<0.001	84.972	-1.403 (-1.80 to -1.00) (4)		
Vigorous	10	-0.924	-1.47	-0.38	0.001	85.472	Unchanged		
Aerobic	30	-1.156	-1.46	-0.85	<0.001	81.392	-1.264 (-1.59 to -0.94) (2)		
Resistance	7	-1.042	-1.87	-0.22	0.013	87.944	Unchanged		
Mixed‡	10	-0.455	-0.80	-0.11	0.009	80.237	Unchanged		
Group exercise†									
Yes	27	-0.848	-1.10	-0.59	<0.001	80.503	Unchanged		
No	13	-0.802	-1.24	-0.36	<0.001	83.312	-0.881 (-1.32 to -0.44) (1)		
Supervisiont									
Yes§	40	-1.026	-1.28	-0.77	<0.001	83.926	-1.115 (-1.38 to -0.85) (2)		
No	6	-0.451	-0.91	0.00	0.052	63.553	-0.122 (-0.63 to 0.39) (3, right of mean)		
Type of supervision†									
Exercise professional	18	-0.984	-1.34	-0.63	<0.001	78.879	Unchanged		
Other professional/student	14	-1.278	-1.81	-0.74	<0.001	85.356	Unchanged		
Sample size intervention arm†									
n≥25	12	-0.532	-0.81	-0.26	<0.001	81.445	Unchanged		
n<25	35	-1.166	-1.49	-0.84	<0.001	81.239	-1.370 (-1.72 to -1.02) (4)		
n≥10	34	-0.868	-1.11	-0.63	<0.001	84.568	-0.913 (-1.16 to -0.67) (1)		
	13	-1.281	-1.87	-0.70	<0.001	75.817	-1.568 (-2.22 to -0.91) (2)		

[†]Data for a second intervention group within the same study were included for these analyses.

Subgroup analyses with health education, with light exercise interventions, or with unsupervised training only including small numbers of analysed studies showed comparable SMDs but no significant effects. Subgroup analyses with studies with low or moderate risk of bias confirm results by showing similar outcomes (see online supplemental table 6) as well as subgroup analyses for studies with the diagnosis of MDD and dysthymia (see online supplemental table 7).

Adverse events and side effects

In 10 studies, it was documented that no (serious) adverse events occurred. ⁵² ⁶² ⁶³ ⁶⁹ ⁷³ ⁷⁴ ⁸⁰⁻⁸² Three of these studies reported minor adverse events like muscle or joint pain, headache and fatigue. ⁵² ⁷⁰ ⁷⁴ One study reported that adverse events occurred but did not provide further information. ⁷⁹ Three studies reported few side effects like worsening of pre-existing orthopaedic injuries or admittance to psychiatric ward due to major depression. ⁴⁶ ⁶⁶ ⁷¹

[#]Mixed exercise=aerobic and resistance exercise.

[§]Two studies were partly supervised, see online supplemental table 5).

MDD, major depressive disorder; RCT, randomised clinical trials; SMD, standard mean difference




Figure 1 Flowchart of study selection. Flowchart adapted from the PRISMA 2020 statement.⁴² RCT, randomised controlled trial.

Meta-regression

Meta-regression (see table 2) was calculated for the main analysis and MDD only. In the main analysis, duration of trial in weeks moderated the effect of exercise on depression, with shorter trials associated with larger effects (β =0.032, 95% CI 0.01 to 0.09, p=0.032, R²=0.06). For MDD only, higher antidepressant use by the control group was associated with smaller effects (β =-0.013, 95% CI -0.02 to -0.01, p=0.012, R²=0.28). A meta-regression with studies with low and moderate risk of bias (see online supplemental table 8) rendered a moderating effect of duration of trials overall (β =0.064, 95% CI 0.01 to 0.126, p=0.04, R²=0.12) as well as for MDD only (β =0.070, 95% CI 0.01 to 0.14, p=0.034, R²=0.26).

Mean change and numbers needed to treat (NNT)

We found a mean change of -4.70 points (95% CI -6.25 to -3.15, p<0.001, n=685) on the HAM-D and for the BDI of -6.49 points (95% CI -8.55 to -4.42, p<0.001, n=275) as an additional improvement effect of exercise over control conditions. The calculated NNT was 2.0 (95% CI 1.68 to 2.59) for the main-analysis, and 2.8 (95% CI 1.94 to 5.22) for the low risk of bias studies. For MDD, only the NNT was 1.9 (95% CI 1.49 to 2.99) and 1.6 (95% CI 1.58 to 2.41) in supervision by other professionals/students.

DISCUSSION

This is the largest meta-analysis investigating the effects of exercise for depressive symptoms within samples with diagnosed or indicated depression. Among 41 RCTs, we found that exercise interventions had a large effect favouring exercise over control conditions. Publication bias tests indicate an underestimation of this effect. Subgroup analyses resolved several key questions that lacked clarity from previous reviews; ^{17–20} specifically, the

positive effect of exercise remained significant regardless of risk of bias, depression classification, exercise type, group setting, type of supervision or sample size. Subgroup analyses with health education (k=3), with light exercise interventions (k=2)or with unsupervised training (k=6) showed comparable SMDs but no statistical significance, which can be attributable to the lack of power due to the small numbers of studies included in the subgroup analyses. Surprisingly, the combination of mixed aerobic and resistance training showed smaller effects than aerobic or resistance training as single interventions. We also found a decline in ES from large to moderate for studies with sample sizes in the intervention arm of 25 or more participants. Focusing on solely diagnosed MDD, significant effects of exercise were found for all subgroup analyses except for light and mixed exercise, unsupervised training and for studies with some concern for risk of bias which can again be attributable to a lack of power due to the small number of included studies in the analyses (k=2 to 3). Limiting analyses to studies with low risk of bias and some concerns according to ROB 2 reveal similar results but with ESs declining from high to moderate for most analyses (see online supplemental table 6). Meta-regressions indicated a moderating effect of trial duration favouring shorter interventions and remained robust in meta-regressions without studies of high risk of bias. Regarding the type of exercise, most trial arms (k=30) investigated aerobic exercise detecting large effects followed by resistance training with comparable outcomes. In terms of the exercise intensity, only two arms investigated light intensity exercise while 26 and 10 trials applied moderate and vigorous intensity respectively, with all trials evidencing large effects. Supervised exercise revealed large ESs compared with unsupervised exercise with small effects. Minimal differences were detected between group and non-group exercise interventions favouring group exercise, with both showing large effects.

Review




Figure 2 Meta-analysis of overall studies. N, preintervention n, postintervention, SMD, standardised difference.

Moderator	Number of RCTs	β	95% CI		P value	R²‡
Main analysis						
Mean age exercise	30	0.014	0.00	0.03	0.046	0.02
Mean age control	30	0.014	0.00	0.03	0.041	0.02
Duration of trial (in weeks)*	46	0.047	0.00	0.09	0.032	0.06
Weekly frequency*	46	0.004	-0.17	0.18	0.959	0.00
Minutes per session*	42	0.008	-0.01	0.02	0.268	0.00
Sample size†	41	0.002	-0.00	0.01	0.160	0.00
Mean age exercise	15	0.009	-0.02	0.04	0.585	0.00
Mean age control	15	0.013	-0.02	0.05	0.432	0.00
Duration of trial (in weeks)*	22	0.035	-0.02	0.09	0.218	0.01
Weekly frequency*	22	0.023	-0.20	0.25	0.844	0.00
Minutes per session*	20	-0.005	-0.03	0.02	0.746	0.03
Sample sizet	20	0.008	-0.00	0.02	0.090	0.04
*Data for a second intervention groi †Average sample size pre-post inter ‡R ² equal to R ² analogue. RCT, randomised controlled trial.		vere included for	these analyses.			

Intervention arms with samples sizes ≥ 25 revealed moderate effects (see table 1 for details).

A recent meta-analysis of Cuijpers *et al*⁸⁵ found a moderate ES for psychotherapy treatment for depression across all age groups (g=0.75), and also when solely including studies with low risk of bias (g=0.51); while in terms of antidepressant efficacy, Cipriani *et al*⁸⁶ found medication to be more effective in comparison to placebo with Odds ratio of 2.13 indicating a small ES of d=0.417. This is notable as the presented results suggest exercise to qualify as an efficacious treatment option for depressive symptoms among individuals with depression.

These results extend the findings from an earlier meta-analysis of Schuch *et al*²⁰ (based on 25 studies including 1487 participants, revealing high heterogeneity of I² 82.10%). Notably, the present findings are based on an additional 17 studies ⁴⁴ ⁴⁵ ⁴⁸ ⁵² ⁵³ ⁵⁵ ⁵⁹ ⁶² ⁶⁷⁻⁶⁹ ⁷¹ ⁷⁴ ⁷⁸ ⁷⁹ ⁸⁴ since Schuch *et al*'s²⁰ review and 4⁴⁵ ⁵⁵ ⁶⁸ ⁷⁴ studies following the most recent meta-analysis by Carneiro *et al*, ¹⁷ comprising only 15 studies focusing on different inclusion criteria including medication in treatment and control arm conditions.

In contrast to Krogh et al, 18 the analyses including only low risk of bias studies resulted in moderate effects with wide 95% CIs ranging from -0.99 to -0.34. Of note, we used the current risk of bias tool (RoB2) and included a greater number of low risk of bias trials compared with Krogh et al's 18 meta-analysis (11 vs 4). To reduce risk of bias, we compared exercise treatment groups with non-exercising control groups only. From the included 35 trials in the Cochrane Meta-Analysis by Cooney et al²¹ consisting of 1356 participants, they reported 63% heterogeneity for the main analyses, the current review excluded 13 of these studies as groups were labelled as either 'controls' (ie, they received psychotherapy or pharmacotherapy) or groups labelled as 'exercise' groups (ie, they received a combination of exercise and another form of therapy or no therapy at all) or participants did not meet criteria for depression (see Ref. 22 for a critical appraisal). Krogh et al¹⁸ also included 35 trials comprising 2498 participants with high heterogeneity (I²=81%) of which the current review excluded 17 studies with control groups that received stretching, relaxation or compared exercise to psychotherapy, medication or combined exercise with psychotherapy. Morres et al¹⁹ included 11 trials involving 455 patients revealing low and non-statistically significant heterogeneity (I²=21%) but focused on aerobic exercise only; however, five of these studies were excluded from the current review because they included medication, active control conditions or cognitive or counselling therapy as comparator conditions. Carneiro et al¹⁷ included 15 studies in their meta-analysis with a total sample size of 1532 individuals focusing on pharmacological treatment, exercise treatment and combined exercise with psychotherapy, of which the current review excluded 7 studies due to the inclusion of pharmacological therapy as a comparator condition either alone or in combination with psychotherapy. A further study was also excluded because participants were offered internet guided text modules on how to become more physically active but no actual exercise intervention was administered. Carneiro et al. 17 overall reported moderate heterogeneity (I²= 33%).

This summary reveals that a notable methodological limitation based on the former published meta-analyses in this field, included a proportion of trials with questionable intervention or control group conditions, which resulted in the inability to detect the effect of exercise per se (while excluding other forms of interventions). Hence, this notable shortcoming was addressed in this current meta-analytic review. Although we explored heterogeneity with sub-analyses and meta regression, we also

found similar large heterogeneity comparable to previous larger meta-analyses^{18 20 21} which guarantees comparability, yet needs to be considered when interpreting the results.

Our meta-regressions indicated that shorter trials are associated with larger effects than longer trials. A possible explanation is that larger trials had more dropouts, and higher dropout rates can reduce the effect in intention to treat analyses. ⁸⁷ Alternatively, it is possible that the effect wanes with the time. However, all but three studies had interventions lasting 16 weeks or less and further studies with longer follow-ups should confirm this effect. ⁸⁸ Also, we have found that studies in which control groups had a higher percentage of participants taking antidepressants identified smaller effects of exercise. This is expected as the difference on the magnitude of the improvement on depressive symptoms is smaller when exercise is compared with effective treatments, such as the use of pharmacological antidepressants, or when compared with controls without any treatment. ⁸⁷

Clinical implications included that if 100 people were each in the control and the exercise group, 20 participants in the control and 54 in the exercise group for the main analysis and 43 in the exercise group for the low risk of bias studies, analyses can be expected to have favourable outcomes.⁸⁹ The NNT for the mainanalysis was 2, while it was 2.8 in the low risk of bias studies, 1.9 in MDD only and 1.6 in supervision by other professionals/ students. This effect is comparable to recent meta-analyses with psychotherapy revealing a NNT of 2.5 for the main analyses and 3.5 in the low risk of bias studies and for medication of 4.3.85 86 Based on a NNT of 2 for the main analyses this means that for every two people treated with exercise, it is expected at least one to have a large magnitude reduction in depressive symptoms.⁴³ Furthermore, exercise showed an additional declining effect over control conditions of -4.70 points in the HAM-D as a diagnostic clinician measure in 16 studies and -6.49 in the BDI in eight studies indicating a clinically meaningful reduction of depressive symptoms from moderate to mild depression. According to the NICE guidelines, a three-point change is indicated as clinically meaningful for both measures. 16

Limitations

We acknowledge that limitations lie in the high heterogeneity of the included studies that can stem from different control group conditions, cultural backgrounds, gender distribution, variable forms of assessments and diagnosis of depression severity or MDD. Notwithstanding, we have performed several subgroup analyses and meta-regressions to explore the sources of this heterogeneity. Additionally, most of the included studies comprised small sample sizes for example, 13 studies with intervention arms of ≤ 10 participants in each group postintervention which we addressed with subanalyses. However, studies with larger samples sizes showed smaller but still moderate effects. Some subanalyses showed non-significant results as they lacked power due to the small number of studies included. In principle, the overreliance of significance testing should be avoided and interpretation of results based on SMD and 95% CI along with p values. Mostly seen wider ranges in CIs within the analyses can stem to a large extent from smaller studies (eg, 10 studies with n<10) and small number of studies in the subanalyses (especially less than k=10) which brings some uncertainty pertaining to the true effect. However, for the main analyses, 95% CIs were documented for exercise conditions comprising moderate intensity, aerobic exercise, group exercise and supervised exercise (ranging between 26 and 41 included studies), thus indicating

Review

moderate to large effects even for the lower limits. These outcomes provide adequate evidence to support the recommendation that exercise has utility in treating depression based on the aforementioned conditions. Long-term effects could not be investigated due to missing follow-up data for most studies. Moreover, it was not possible to control for placebo effects due to the nature of the interventions. Furthermore, 6 out of the 41 included studies were published prior to 2001 and can therefore be assigned to the pre-CONSORT era. This means that these earlier trials might not reflect the current standards and/or feature incomplete reporting of methodological details that was introduced with the CONSORT guidelines and checklist, therefore increasing scope in biased risk assessments and heterogeneity.^{22,90}

Further steps need to be undertaken to consider exercise as a first-line treatment for depression alongside psychotherapy and medication, including conducting non-inferiority trials to demonstrate that exercise is non-inferior to current first line treatments, and evidence that exercise is effective at long-term follow-ups. Future large-scale research studies should also investigate which patients benefit most from which exercise condition and identify any groups for whom exercise might not be the optimal treatment choice. It is noteworthy that the studies included in the current and former reviews consisted of samples which met the trial inclusion criteria comprising individuals that were willing, motivated and physically able to take part in the exercise regimen (eg, assessed by the Physical Activity Readiness Questionnaire⁹¹) and excluded individuals with diagnoses that exercise may pose a risk (for example, individuals with cardiovascular diseases that require physician guidance to undertake exercise). Further, adverse events and outcomes due to exercise may occur in rare instances (nevertheless, they should be reported which was not documented for the majority of studies in this review), and not everyone has access to any form of exercise or exercise with the needed quality (eg, with a former sport medical examination). It is also noteworthy that the included studies were mainly conducted in high-income and upper-middle income countries, for example, no study was identified from the African continent. Future study designs should consider these relevant points including motivational aspects of attendance and samples from developing countries or rural areas to increase the generalisability of the results for healthcare.

Further strengthening the evidence base for exercise also has utility as it may be a less stigmatising treatment option for depressed individuals who may be reluctant to seek and adhere to psychotherapy and/or medication.

CONCLUSION

The findings from this review represent the most up to date and comprehensive meta-analysis of the available evidence and further supports the use of exercise focusing specifically on supervised and group exercise with moderate intensity and aerobic exercise regimes. This offers a further evidence-based treatment option for the large amount of untreated individuals with depression, including individuals who refuse or cannot tolerate medication and/or psychotherapy. However, given the high heterogeneity and mainly small and selected samples of the included studies, this requires individual decisions involving the treating physician to determine if and which conditions of exercise are the optimal treatment of choice while also recognising the potential synergistic effects of exercise in managing both physical and mental well-being. Updated guidelines as

well as routine clinical decisions regarding interventions for treating depression should consider the current findings. This is particularly timely, following the post COVID-19 pandemic, given that rates of depression have continued to increase worldwide.

Author affiliations

¹Social and Preventive Medicine, Department of Sports and Health Sciences, Intra faculty unit "Cognitive Sciences", Faculty of Human Science and Faculty of Health Sciences Brandenburg, Research Area Services Research and e-Health, Potsdam, Brandenburg, Germany

²School of Psychological Sciences, Centre for Emotional Health, Macquarie University, Sydney, New South Wales, Australia

³Department of Rehabilitation Sciences, University of Leuven, Leuven, Belgium ⁴Physiotherapy Department, South London and Maudsley NHS Foundation Trust; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK

⁵Division of Psychology and Mental Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; NICM Health Research Institute, Western Sydney University, Westmead Australia; Greater Manchester Mental Health NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK ⁶Discipline of Psychiatry and Mental Health, UNSW Sydney, Sydney New South Wales, Australia; Ingham Institute of Applied Medical Research, UNSW, Liverpool BC, New South Wales, Australia

⁷School of Psychiatry, UNSW, Sydney, New South Wales, Australia ⁸Epidemiology of Psychiatric Conditions, Substance use and Social Environment (EPiCSS), Department of Public Health Sciences, Karolinska Institute Solna, Solna, Sverige. Sweden

⁹Department of Sports Methods and Techniques, Federal University of Santa Maria, Santa Maria, Brazil

¹⁰Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
 ¹¹Universidad Autónoma de Chile, Providencia, Chile

Twitter Andreas Heissel @AndreasHeissel, Luisa Leonie Brokmeier @LuisaBrokmeier, Maria Kangas @MariaKangas88, Davy Vancampfort @davyvancampfort, Philip B Ward @PhilWardAu, Simon Rosenbaum @simon_rosenbaum and Felipe Schuch @SchuchFelipe

Contributors AH and FS conceived and designed the study. AH, LLB and FS had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. NS/LLB and DH did the literature search. AH, LLB, NS, DH and FS conducted the analyses, interpreted the data and wrote the first draft of the manuscript. All authors contributed to critical revision of the report for important intellectual content.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests AH is founder and CEO of the Centre for Emotional Health Germany GmbH supported by the Potsdam Transfer Centre from the University of Potsdam, BS has an NIHR Advanced fellowship (NIHR-301206, 2021–2026) and is coinvestigator on an NIHR program grant: Supporting Physical and Activity through Co-production in people with Severe Mental Illness (SPACES). BS is on the Editorial board of Mental Health and Physical Activity and The Brazilian Journal of Psychiatry. BS has received honorarium from a coedited book on exercise and mental illness and advisory work from ASICS for unrelated work. MK is on the Editorial boards for Behavior Therapy (Associate Editor), Stress and Health (Sections Editor), Psychological Bulletin, and Behaviour Research and Therapy. JF is supported by a UK Research and Innovation Future Leaders Fellowship (MR/T021780/1) and has received honoraria / consultancy fees from Atheneum, Informa, Gillian Kenny Associates, Big Health, Wood For Trees, Nutritional Medicine Institute, Angelini, ParachuteBH, Richmond Foundation and Nirakara, independent of this work. FS is on the Editorial board of Mental Health and Physical Activity, The Brazilian Journal of Psychiatry and Journal Brasileiro de Psiquiatria. FS has received honorarium from a co-edited book on lifestyle and mental illness. The other authors declare no funding, editorial or potential competing interests.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability

of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Andreas Heissel http://orcid.org/0000-0001-9270-7027
Darlene Heinen http://orcid.org/0000-0001-9172-9718
Luisa Leonie Brokmeier http://orcid.org/0000-0003-4136-9704
Maria Kangas http://orcid.org/0000-0001-8693-2949
Davy Vancampfort http://orcid.org/0000-0002-4592-8625
Brendon Stubbs http://orcid.org/0000-0001-7387-3791
Joseph Firth http://orcid.org/0000-0002-618-2752
Philip B Ward http://orcid.org/0000-0002-5779-7722
Simon Rosenbaum http://orcid.org/0000-0002-8984-4941
Mats Hallgren http://orcid.org/0000-0002-599-2403
Felipe Schuch http://orcid.org/0000-0002-5190-4515

REFERENCES

- 1 Bromet E, Andrade LH, Hwang I, et al. Cross-National epidemiology of DSM-IV major depressive episode. BMC Med 2011;9:90.
- 2 James SL, Abate D, Abate KH. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018;392:S0140-6736(18)32279-7:1789–858:.
- 3 World Health Organization. Depression and other common mental disorders: global health estimates. 2017. Available: https://www.who.int/publications/i/item/depression-global-health-estimates [Accessed 15 Oct 2021].
- 4 Allen SF, Stevenson J, Lazuras L, et al. The role of the COVID-19 pandemic in altered psychological well-being, mental health and sleep: an online cross-sectional study. Psychol Health Med 2022;27:343–51.
- 5 González-Sanguino C, Ausín B, Castellanos MA, et al. Mental health consequences of the covid-19 outbreak in Spain. A longitudinal study of the alarm situation and return to the new normality. Prog Neuropsychopharmacol Biol Psychiatry 2021;107:S0278-5846(20)30535-2:110219:.
- 6 Veldhuis CB, Nesoff ED, McKowen ALW, et al. Addressing the critical need for long-term mental health data during the COVID-19 pandemic: changes in mental health from April to September 2020. Prev Med 2021;146:S0091-7435(21)00049-9:106465:.
- 7 Santomauro DF, Mantilla Herrera AM, Shadid J. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet* 2021;398:S0140-6736(21)02143-7:1700—12:.
- 8 Pfefferbaum B, North CS. Mental health and the covid-19 pandemic. N Engl J Med 2020;383:510–2.
- 9 Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2021:55:7–117.
- 10 Cuijpers P, Oud M, Karyotaki E, et al. Psychologic treatment of depression compared with pharmacotherapy and combined treatment in primary care: a network metaanalysis. Ann Fam Med 2021;19:262–70.
- 11 Jakobsen JC, Katakam KK, Schou A, et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis. BMC Psychiatry 2017;17:58.
- 12 Wise J. Nice guidance on depression: 35 health organisations demand " full and proper " revision. BMJ 2019;12356.
- 13 Thornicroft G, Chatterji S, Evans-Lacko S, et al. Undertreatment of people with major depressive disorder in 21 countries. Br J Psychiatry 2017;210:119–24.
- 14 Kessler RC. The costs of depression. Psychiatr Clin North Am 2012;35:1–14.
- 15 World Health Organization. WHO guidelines on physical activity and sedentary behaviour. 2020.
- 16 National Institute for Health and Care Excellence. Depression: the treatment and management of depression in adults. 2018. Available: https://www.nice.org.uk/ guidance/cg90/ [Accessed 6 Nov 2021].
- 17 Carneiro L, Silva F, Vasoncelos-Raposo J, et al. Exercise as a complementary therapy for depression: a systematic review and meta-analysis of randomized controlled trials and bioinformatics exploration gene network model. In Review [Preprint].
- 18 Krogh J, Hjorthøj C, Speyer H, et al. Exercise for patients with major depression: a systematic review with meta-analysis and trial sequential analysis. BMJ Open 2017:7:e014820.
- 19 Morres ID, Hatzigeorgiadis A, Stathi A, et al. Aerobic exercise for adult patients with major depressive disorder in mental health services: a systematic review and metaanalysis. *Depress Anxiety* 2019;36:39–53.

- 20 Schuch FB, Vancampfort D, Richards J, et al. Exercise as a treatment for depression: a meta-analysis adjusting for publication bias. J Psychiatr Res 2016;77:S0022-3956(16)30038-3:42–51:.
- 21 Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database Syst Rev 2013;2013:CD004366.
- 22 Ekkekakis P. Honey, I shrunk the pooled SMD! guide to critical appraisal of systematic reviews and meta-analyses using the Cochrane review on exercise for depression as example. Mental Health and Physical Activity 2015;8:21–36.
- 23 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 2009;6:e1000097.
- and meta-analyses: the PRISMA statement. *PLOS Med* 2009;6:e1000097.

 24 Page MJ, McKenzie JE, Bossuyt PM, *et al*. The PRISMA 2020 statement: an updated
- guideline for reporting systematic reviews. BMJ 2021;372:n71.
 Ardern CL, Büttner F, Andrade R, et al. Implementing the 27 PRISMA 2020 statement items for systematic reviews in the sport and exercise medicine, musculoskeletal rehabilitation and sports science fields: the persist (implementing PRISMA in exercise, rehabilitation, sport medicine and sports science) guidance. Br J Sports Med 2022;56:175–95.
- 26 Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978;35:773–82.
- 27 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM IV). American Psychiatric Press, 2000.
- 28 World Health Organization. ICD-10. 2016. Available: https://icd.who.int/browse10/2016/en [Accessed 1 Jun 2021].
- 29 Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71.
- 30 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
- 31 Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. *Public Health Rep* 1985:100:126–31.
- 32 Larkey L, Jahnke R, Etnier J, et al. Meditative movement as a category of exercise: implications for research. J Phys Act Health 2009;6:230–8.
- 33 Sterne JAC, Savović J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:14898.
- 34 Morris SB. Estimating effect sizes from pretest-posttest-control group designs. Organizational Research Methods 2008;11:364–86.
- 35 Higgins JPT, Thompson SG, Deeks JJ, *et al*. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
- 36 Jakobsen JC, Wetterslev J, Winkel P, et al. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol 2014:14:120.
- 37 Begg CB, Mazumdar M. Operating characteristics of a RANK correlation test for publication bias. *Biometrics* 1994;50:1088–101.
- Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
- 39 Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56:455–63.
- 40 Rosenthal R, Kleid JJ, Cohen MV. Abnormal mitral valve motion associated with ventricular septal defect following acute myocardial infarction. Am Heart J 1979;98:638–41.
- Borenstein M, Hedges L, Higgins J, et al. Comprehensive meta-analysis software version 3. 2013.
- 42 Lenhard W, Lenhard A. Berechnung von effektstärken. in: psychometrica. Available: https://www.psychometrica.de/effektstaerke.html#nntconv [Accessed 3 Dec 2021].
- 43 Furukawa TA, Leucht S. How to obtain nnt from cohen's D: comparison of two methods. PLOS ONE 2011;6:e19070.
- 44 Mather AS, Rodriguez C, Guthrie MF, et al. Effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder: randomised controlled trial. Br J Psychiatry 2002;180:411–5.
- 45 Abdelbasset WK, Alqahtani BA, Elshehawy AA, et al. Examining the impacts of 12 weeks of low to moderate-intensity aerobic exercise on depression status in patients with systolic congestive heart failure-a randomized controlled study. Clinics (Sao Paulo) 2019:74:e1017.
- 46 Brenes GA, Williamson JD, Messier SP, et al. Treatment of minor depression in older adults: a pilot study comparing sertraline and exercise. Aging Ment Health 2007:11:61–8.
- 47 Doyne EJ, Ossip-Klein DJ, Bowman ED, et al. Running versus weight lifting in the treatment of depression. *J Consult Clin Psychol* 1987;55:748–54.
- 48 Gao L, Zhang L, Qi H, et al. Middle-Aged female depression in perimenopausal period and square dance intervention. *Psychiatr Danub* 2016;28:372–8.
- 49 Hallgren M, Kraepelien M, Öjehagen A, et al. Physical exercise and Internet-based cognitive-behavioural therapy in the treatment of depression: randomised controlled trial. Br J Psychiatry 2015;207:227–34.
- 50 Hemat-Far A, Shahsavari A, Mousavi SR. Effects of selected aerobic exercises on the depression and concentrations of plasma serotonin in the depressed female students aged 18 to 25. J Appl Res 2012;12:47–52.
- 51 Huang TT, Liu CB, Tsai YH, et al. Physical fitness exercise versus cognitive behavior therapy on reducing the depressive symptoms among community-

Review

- dwelling elderly adults: a randomized controlled trial. *Int J Nurs Stud* 2015;52:S0020-7489(15)00190-X:1542–52:.
- 52 Legrand FD. Effects of exercise on physical self-concept, global self-esteem, and depression in women of low socioeconomic status with elevated depressive symptoms. J Sport Exerc Psychol 2014;36:357–65.
- 53 Lok N, Lok S, Canbaz M. The effect of physical activity on depressive symptoms and quality of life among elderly nursing home residents: randomized controlled trial. Arch Gerontol Geriatr 2017;70:S0167-4943(17)30042-0:92–8:.
- 54 McNeil JK, LeBlanc EM, Joyner M. The effect of exercise on depressive symptoms in the moderately depressed elderly. *Psychol Aging* 1991;6:487–8.
- 55 Makizako H, Tsutsumimoto K, Doi T, et al. Exercise and horticultural programs for older adults with depressive symptoms and memory problems: a randomized controlled trial. J Clin Med 2019;9:99.
- 56 Nimmo MA, McLean D, Mutrie N, et al. An holistic approach to recovery from an overuse injury in a games player. Br J Sports Med 1986;20:103–6.
- 57 Nabkasorn C, Miyai N, Sootmongkol A, *et al*. Effects of physical exercise on depression, neuroendocrine stress hormones and physiological fitness in adolescent females with depressive symptoms. *Eur J Public Health* 2006;16:179–84.
- 58 Orth DK. Clinical treatments of depression. West Virginia University, 1979.
- 59 Prakhinkit S, Suppapitiporn S, Tanaka H, et al. Effects of buddhism walking meditation on depression, functional fitness, and endothelium-dependent vasodilation in depressed elderly. J Altern Complement Med 2014;20:411–6.
- 60 Seitaro JL. Aerobic exercise and group counseling in the treatment of anxiety and depression. University of Maryland, 1985.
- 61 Shahidi M, Mojtahed A, Modabbernia A, et al. Laughter yoga versus group exercise program in elderly depressed women: a randomized controlled trial. Int J Geriatr Psychiatry 2011;26:322–7.
- 62 Sims J, Hill K, Davidson S, et al. Exploring the feasibility of a community-based strength training program for older people with depressive symptoms and its impact on depressive symptoms. BMC Geriatr 2006;6:18.
- 63 Sims J, Galea M, Taylor N, et al. Regenerate: assessing the feasibility of a strength-training program to enhance the physical and mental health of chronic post stroke patients with depression. Int J Geriatr Psychiatry 2009;24:76–83.
- 64 Williams CL, Tappen RM. Exercise training for depressed older adults with Alzheimer's disease. Aging Ment Health 2008;12:72–80.
- 65 Pfaff JJ, Alfonso H, Newton RU, et al. ACTIVEDEP: a randomised, controlled trial of a home-based exercise intervention to alleviate depression in middle-aged and older adults. Br J Sports Med 2014;48:226–32.
- 66 Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med 2007;69:587–96.
- 67 Carneiro LSF, Fonseca AM, Vieira-Coelho MA, et al. Effects of structured exercise and pharmacotherapy vs. pharmacotherapy for adults with depressive symptoms: a randomized clinical trial. J Psychiatr Res 2015;71:S0022-3956(15)00268-X:48–55:.
- 68 Chau RMW, Tsui AYY, Wong EYW, et al. Effectiveness of a structured physical rehabilitation program on the physical fitness, mental health and pain for chinese patients with major depressive disorders in hong kong - a randomized controlled trial with 9-month follow-up outcomes. Disabil Rehabil 2022;44:1294–304.
- 69 Cheung LK, Lee S. A randomized controlled trial on an aerobic exercise programme for depression outpatients. Sport Sci Health 2018;14:173–81.
- 70 Danielsson L, Papoulias I, Petersson EL, et al. Exercise or basic body awareness therapy as add-on treatment for major depression: a controlled study. J Affect Disord 2014;168:S0165-0327(14)00417-0:98–106:.
- 71 Doose M, Ziegenbein M, Hoos O, et al. Self-Selected intensity exercise in the treatment of major depression: a pragmatic RCT. Int J Psychiatry Clin Pract 2015:19:266–75.
- 72 Epstein D. Aerobic activity versus group cognitive therapy. In: An evaluative study of contrasting interventions for the alleviation of clinical depression. University of Nevada, 1986.

- 73 Gary RA, Dunbar SB, Higgins MK, et al. Combined exercise and cognitive behavioral therapy improves outcomes in patients with heart failure. J Psychosom Res 2010:69:119–31
- 74 La Rocque CL, Mazurka R, Stuckless TJR, et al. Randomized controlled trial of bikram yoga and aerobic exercise for depression in women: efficacy and stress-based mechanisms. J Affect Disord 2021;280(Pt A):S0165-0327(20)32912-8):457–66:.
- 75 Mota-Pereira J, Silverio J, Carvalho S, et al. Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder. J Psychiatr Res 2011:45:1005–11.
- 76 Oertel-Knöchel V, Mehler P, Thiel C, et al. Effects of aerobic exercise on cognitive performance and individual psychopathology in depressive and schizophrenia patients. Eur Arch Psychiatry Clin Neurosci 2014;264:589–604.
- 77 Pilu A, Sorba M, Hardoy MC, et al. Efficacy of physical activity in the adjunctive treatment of major depressive disorders: preliminary results. Clin Pract Epidemiol Ment Health 2007:3:8.
- 78 Roy A, Govindan R, Muralidharan K. The impact of an add-on video assisted structured aerobic exercise module on mood and somatic symptoms among women with depressive disorders: study from a tertiary care centre in India. Asian J Psychiatr 2018;32:S1876-2018(17)30706-2:118–22:.
- 79 Schneider KL, Panza E, Handschin B, et al. Feasibility of pairing behavioral activation with exercise for women with type 2 diabetes and depression: the get it study pilot randomized controlled trial. Behav Ther 2016;47:S0005-7894(15)00115-X:198–212:.
- 80 Schuch FB, Vasconcelos-Moreno MP, Borowsky C, et al. Exercise and severe major depression: effect on symptom severity and quality of life at discharge in an inpatient cohort. J Psychiatr Res 2015;61:S0022-3956(14)00314-8:25–32:.
- 81 Singh NA, Clements KM, Fiatarone MA. A randomized controlled trial of progressive resistance training in depressed elders. J Gerontol A Biol Sci Med Sci 1997:52:M27–35.
- 82 Singh NA, Stavrinos TM, Scarbek Y, et al. A randomized controlled trial of high versus low intensity weight training versus general practitioner care for clinical depression in older adults. J Gerontol A Biol Sci Med Sci 2005;60:768–76.
- 83 Veale D, Le Fevre K, Pantelis C, et al. Aerobic exercise in the adjunctive treatment of depression: a randomized controlled trial. J R Soc Med 1992;85:541–4.
- 84 Vieira JLL, Porcu M, Rocha PGM da. A prática de exercícios físicos regulares como terapia complementar AO tratamento de mulheres CoM depressão. J Bras Psiquiatr 2007;56:23–8.
- 85 Cuijpers P, Karyotaki E, Eckshtain D, et al. Psychotherapy for depression across different age groups: a systematic review and meta-analysis. JAMA Psychiatry 2020:77:694–702
- 86 Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Focus (Am Psychiatr Publ) 2018;16:420–9.
- 87 Stubbs B, Vancampfort D, Rosenbaum S, et al. Challenges establishing the efficacy of exercise as an antidepressant treatment: a systematic review and meta-analysis of control group responses in exercise randomised controlled trials. Sports Med 2016;46:699–713.
- 88 Gupta SK. Intention-To-Treat concept: a review. Perspect Clin Res 2011;2:109–12.
- 89 Magnusson K. Interpreting cohen's d effect size. 2021. Available: https://rpsychologist. com/cohend/ [Accessed 3 Dec 2021].
- 90 Moher D, Jones A, Lepage L, et al. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001;285:1992–5.
- 91 Craig CL, Marshall AL, Sjöström M, *et al.* International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* 2003;35:1381–95.

Supplementary Material

Exercise as Medicine for Depressive Symptoms?

A Systematic Review and Meta-analysis with Meta regression

Andreas Heißel, Darlene Heinen, Luisa Leonie Brokmeier, Nora Skarabis, Maria Kangas, Davy Vancampfort, Brendon Stubbs, Joseph Firth, Philip B. Ward, Simon Rosenbaum, Mats Hallgren, Felipe Schuch

- Text 1. Full search terms
- Table 1. Data of Studies Included in Systematic Review
- Table 2. List of excluded studies at full-text screening stage, with brief reasons
- **Table 3.** Risk of Bias Assessments (ROB2)
- Table 4. Summary of included studies
- **Table 5.** Characteristics of included studies
- **Table 6.** Subgroup Meta-Analysis of studies included in the quantitative analyses with low and moderate risk of bias
- **Table 7.** Subgroup analysis for studies with MDD diagnosis
- **Table 8.** Meta regression of moderators/correlates of effects of exercise on depression for studies with low and moderate risk of bias
- Figure 1. Funnel Plot of Standard Error by SMD

Supplementary Text 1. Full search terms

MeSH terms

((exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR physical medicine OR resistance OR lift*) AND (depression OR dysthymia) AND (randomized controlled trial OR clinical trial))

Cochrane/ Embase

(exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR "physical medicine" OR resistance OR lift*):ti,ab,kw AND (depression OR dysthymia):ti,ab,kw AND (randomized control trial" OR "randomized clinical trial):ti,ab,kw in Trials (Word variations have been searched)

PubMed

((exercis*[Title/Abstract] OR aerobic*[Title/Abstract] OR running[Title/Abstract] OR jogging[Title/Abstract] OR walk*[Title/Abstract] OR hiking[Title/Abstract] OR swim*[Title/Abstract] OR aquatic*[Title/Abstract] OR cycling[Title/Abstract] OR bicycl*[Title/Abstract] OR strength*[Title/Abstract] AND activit*[Title/Abstract] OR fitness[Title/Abstract] OR train*[Title/Abstract] OR physical medicine[Title/Abstract] OR resistance[Title/Abstract] OR lift*[Title/Abstract]) AND (depression[Title/Abstract] OR dysthymia[Title/Abstract])) AND (randomized controlled trial[Title/Abstract]) OR clinical trial[Title/Abstract])

PsychINFO

(exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR physical medicine OR resistance OR lift*) AND (depression OR dysthymia) AND (randomized controlled trial OR clinical trial)

SPORTDiscus

(exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR physical medicine OR resistance OR lift*) AND (depression OR dysthymia) AND (randomized controlled trial OR clinical trial)

Medline

((TS=(exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR physical medicine OR resistance OR lift*)) AND TS=(depression OR dysthymia)) AND TS=(randomized controlled trial OR clinical trial)

Scopus

TITLE-ABS-KEY ((exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* AND activit* OR fitness OR train* OR physical AND medicine OR resistance OR lift*) AND (depression OR dysthymia) AND (randomized AND controlled AND trial OR clinical AND trial))

Web of Science

(exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR physical medicine OR resistance OR lift*) AND (depression OR dysthymia) AND (randomized controlled trial OR clinical trial) (Topic)

Study	Sample size	ze (n)	Outcome ^a	Pre (mean	ı (SD))	Post (mea	Post (mean (SD))				Control group condition	Diagnosis
	Exercise	Control		Exercise	Control	Exercise	Control	Type of intervention	Wks	Sessions per wk/ time per session		
Abdelbasset et al, ⁴⁵ 2019	23	23	PHQ-9	16.12 (3.10)	15.95 (3.14)	3.65 (1.21)	8.54 (2.14)	Aerobic exercise	12	3/30-60 min ^b	Usual care (standard medical treatment)	Depressive symptoms
Blumenthal et al, ⁶⁶ 2007 (supervised exercise)	51	49	HAM-D, BDI-II	16.40 (3.70)	17.20 (4.30)	9.20 (6.10)	11.00 (7.00)	Aerobic exercise	16	3/45 min	Placebo	MDD
Blumenthal et al, ⁶⁶ 2007 (homebased exercise)	53	49	HAM-D, BDI-II	17.30 (4.60)	17.20 (4.30)	10.20 (6.70)	11.00 (7.00)	Aerobic exercise	16	3/45 min	Placebo	MDD
Brenes et al, 46 2007	14	12	HAM-D, GDS	12.70 (3.40)	9.50 (3.70)	7.80 (4.30)	10.90 (5.80)	Mixed exercise	16	3/60 min	Usual care (phone calls to discuss health status)	Depressive symptoms
Carneiro et al, ⁶⁷ 2015	9	10	BDI-II, DASS-21	45.56 (9.65)	46.10 (11.52)	34.89 (10.56)	49.40 (16.72)	Aerobic exercise	16	3/45 min	Usual care (pharmacolog ical therapy)	MDD & Dysthymia
Chau et al, ⁶⁸ 2020	42	42	HAM-D, DASS-21	25.93 (6.59)	25.62 (8.03)	12.57 (8.06)	25.58 (7.81)	Mixed exercise	12	3/60 min	Wait-list	MDD
Cheung et al, ⁴⁸ 2018	17	17	HAM-D	18.50 (3.20)	19.40 (3.60)	9.80 (5.60)	14.50 (5.30)	Aerobic exercise	12	3/40 min	Usual care (usual psychiatric care)	MDD

Danielsson et al, ⁷⁰ 2014	22	20	MADRS	24.60 (4.10)	23.40 (5.00)	-10.30° (1.60)	-4.60° (1.70)	Aerobic exercise	10	2/60 min	Usual care (standard care)	MDD
Doose et al, ⁷¹ 2015	30	16	HAM-D, BDI-II	13.97 (2.58)	14.67 (3.91)	-9.48 ^d (11.38- 7.58)	-1.24 ^d (-3.85-1.37)	Aerobic exercise	8	3/60 min	Wait-list	MDD
Doyne et al, ⁴⁷ 1987 (running condition)	14	11	HAM-D, BDI, DACL	13.36 (4.43)	12.58 (4.58)	6.64 (3.61)	13.58 (5.14)	Aerobic exercise	8	4/25 min	Wait-list	Depressive symptoms
Doyne et al, ⁴⁷ 1987 (weightlifting)	15	11	HAM-D, BDI, DACL	13.80 (7.78)	12.58 (4.58)	5.13 (3.44)	13.58 (5.14)	Resistance exercise	8	4/45 min	Wait-list	Depressive symptoms
Epstein, ⁷² 1986	7	10	BDI, SDS	25.29 (6.52)	22.00 (7.16)	9.00 (10.94)	16.30 (7.44)	Aerobic exercise	8	3/30 min	Wait-list	MDD
Gao et al, ⁴⁸ 2016	26	24	SDS	0.58 (0.10)	0.59 (0.11)	0.43 (0.09)	0.57 (0.10)	Aerobic exercise	12	5/60-90 min ^b	Usual care (lived normally without intervention)	Depressive symptoms
Gary et al, ⁷³ 2010	20	17	HAM-D	15.40 (3.40)	15.20 (3.60)	8.40 (5.60)	9.30 (4.90)	Aerobic exercise	12	3/weekly increase by 5 min to 60 min ^b	Usual care (usually provided	MDD
Hallgren et al, ⁴⁹ 2015	317	312	MADRS	22.20 (6.80)	20.90 (7.50)	11.30 (7.90)	13.80 (8.90)	Mixed exercise	12	3/60 min	Usual care (treatment as usual)	Depressive symptoms
Hemat-Far et al, ⁵⁰ 2012	10	10	BDI	25.00 (5.30)	23.80 (4.70)	16.60 (6.90)	22.80 (4.90)	Aerobic exercise	8	3/40-60 min ^b	Usual care (pursue normal live)	Depressive symptoms
Huang et al, ⁵¹ 2015	19	20	GDS-15	8.63 (3.56)	7.20 (2.19)	4.63 (2.49)	5.20 (1.69)	Mixed exercise	12	3/50 min	Usual care	Depressive symptoms

La Rocque et al, ⁷⁴ 2020	20	15	HAM-D	12.00 (3.77)	13.93 (3.71)	6.75 (6.05)	16.33 (5.84)	Aerobic exercise	8	2/50-60 min ^b	Wait-list	MDD
Legrand et al, ⁵² 2014	22	22	BDI-II	21.67 (6.78)	19.25 (9.34)	12.80 (4.38)	19.67 (8.17)	Aerobic exercise	7	2/30 min	Wait-list	Depressive symptoms
Lok et al, ⁵³ 2017	40	40	BDI	17.46 (8.07)	19.89 (5.00)	11.89 (4.23)	17.71 (4.61)	Aerobic exercise	10	4/70 min	Wait-list	Depressive symptoms
Makizako et al, ⁵⁵ 2019	30	29	GDS-15	7.10 (2.50)	6.40 (2.50)	5.30 (2.50)	5.10 (3.10)	Mixed exercise	20	1/90 min	Health education	Depressive symptoms
Mather et al, ⁴⁴ 2002	43	43	HRSD	16.70 (10.83) ^e	17.40 (10.83) ^e	12.60 (7.02)	13.70 (6.02)	Mixed exercise	10	2/55-65 min ^b	Health education	Depressive symptoms
McNeil et al, ⁵⁴ 1991	10	10	BDI	16.60 (3.10)	15.20 (2.40)	11.10 (3.00)	14.70 (3.70)	Aerobic exercise	6	3/20-40 min ^b	Wait-list	Depressive symptoms
Mota-Pereira et al, ⁷⁵ 2011	19	10	HAM-D, BDI	19.32 (1.69)	13.00 (1.42)	12.48 (1.74)	13.60 (1.34)	Aerobic exercise	6	5/30-45 min ^b	Usual care (pharmacothe rapy)	MDD
Mutrie, ⁵⁶ 1986 (aerobic exercise)	9	7	BDI, POMS	22.44 (6.82)	23.00 (5.80)	9.46 (4.28)	21.42 (5.26)	Aerobic exercise	4	3/20 min	Wait-list	Depressive symptoms
Mutrie, 56 1986 (strength & stretching)	8	7	BDI, POMS	21.86 (4.21)	23.00 (5.80)	14.63 (7.63)	21.42 (5.26)	Mixed exercise	4	3/20 min	Wait-list	Depressive symptoms
Nabkasorn et al, ⁵⁷ 2006	28	31	CES-D	20.10 (0.90)	18.80 (7.00)	14.40 (4.12)	17.50 (4.23)	Aerobic exercise	8	5/50 min	Usual care (usual daily routine)	Depressive symptoms

Oertel-Knöchel et al, ⁷⁶ 2014	8	8	BDI-II	26.25 (10.21)	25.50 (11.83)	18.75 (9.50)	24.00 (13.09)	Aerobic exercise	4	3/75 min	Wait-list	MDD
Orth, ⁵⁸ 1979	3	2	DACL, MMPI	14.00 (3.60)	19.50 (7.00)	7.00 (6.50)	16.50 (2.12)	Aerobic exercise	4	5/30 min	Self- monitoring	Depressive symptoms
Pfaff et al, ⁶⁵ 2014	108	92	SIGMA	21.02 (9.4)	21.66 (8.4)	14.43 (9.8)	14.32 (9.3)	Mixed exercise	12	5/30 min + 3x resistance training	Usual care (usual medical care)	MDD
Pilu et al, ⁷⁷ 2007	10	20	HAM-D	20.50 (7.10)	19.30 (5.70)	8.10 (5.20)	16.70 (9.10)	Resistance exercise	32	2/60 min	Usual care (pharmacothe rapy)	MDD
Prakhinkit et al, ⁵⁹ 2014 (traditional walking)	15	15	TGDS-30	17.30 (1.00)	17.90 (0.70)	15.50 (0.90)	18.60 (0.60)	Aerobic exercise	12	3/20-30 min ^b	Usual care (sedentary control group)	Depressive symptoms
Prakhinkit et al, ⁵⁹ 2014 (Buddhism walking)	15	15	TGDS-30	16.08 (0.90)	17.90 (0.70)	8.60 (0.60)	18.60 (0.60)	Aerobic exercise	12	3/20-30 min ^b	Usual care (sedentary control group)	Depressive symptoms
Roy et al, ⁷⁸ 2018	23	23	HAM-D, DSSS	19.30 (4.83)	16.55 (4.14)	15.00 (4.93)	13.85 (3.16)	Aerobic exercise	1.5	7/20 min	Usual care (treatment as usual)	MDD
Schneider et al, ⁷⁹ 2016	15	14	HAM-D, BDI-II	15.70 (4.60)	17.40 (4.30)	10.60 (6.10)	5.80 (5.41)	Mixed exercise	24	Biweekly 2/20-65 min ^b	Usual care (enhanced usual care condition)	MDD
Schuch et al, 80 2015	25	25	HAM-D	26.52 (1.80)	26.96 (2.70)	7.42 (4.47)	11.12 (4.47)	Aerobic exercise	12	3/unclear	Usual care (treatment as usual)	MDD
Setaro, 60 1985	25	25	MMPI	68.92 (5.27)	68.56 (3.87)	62.00 (6.51)	69.88 (3.96)	Aerobic exercise	10	2/unclear	Usual care (no activity or treatment)	Depressive symptoms

Shahidi et al, ⁶¹ 2011	20	20	GDS-30	15.30 (5.40)	15.20 (3.90)	11.10 (6.20)	15.20 (6.10)	Aerobic exercise	N/A	Unclear/3 0 min	Unclear	Depressive symptoms
Sims et al, ⁶² 2006	14	18	GDS	12.64 (3.61)	12.22 (3.51)	12.23 (5.22)	12.00 (4.26)	Resistance exercise	10	3/unclear	Information and advice for local options of exercise	Depressive symptoms
Sims et al, ⁶³ 2009	23	22	CES-D	15.43 (7.49)	23.27 (8.86)	15.13 (8.49)	20.62 (11.79)	Resistance exercise	10	2/unclear	Wait-list	Depressive symptoms
Singh et al, ⁸¹ 1997	17	15	HAM-D, DSM-IV, BDI, GDS	12.30 (0.90)	11.40 (1.00)	5.30 (1.30)	8.90 (1.30)	Resistance exercise	10	3/50 min	Health education	MDD & Dysthymia
Singh et al, 82 2005 (high intensity)	20	20	HAM-D, GDS	18.00 (4.50)	19.70 (3.90)	8.50 (5.50)	14.40 (6.00)	Resistance exercise	8	3/65 min	Usual care (usual care from GP)	MDD & Dysthymia
Singh et al, 82 2005 (low intensity)	20	20	HAM-D, GDS	19.50 (5.30)	19.70 (3.90)	12.40 (6.30)	14.40 (6.00)	Resistance exercise	8	3/65 min	Usual care (usual care from GP)	MDD & Dysthymia
Veale et al, ⁸³ 1992	48	35	CIS, BDI	35.87 (1.07)	37.57 (1.49)	16.80 (2.06)	26.39 (2.50)	Aerobic exercise	12	3/unclear	Usual care (usual psychiatric treatment)	MDD
Vieira et al, ⁸⁴ 2007	9	9	HAM-D	30.22 (3.04)	31.11 (3.51)	24.88 (2.13)	32.66 (3.12)	Aerobic exercise	12	2/50 min	Usual care	MDD
Williams et al, ⁶⁴ 2008 (mixed exercise)	16	12	CSDD	11.05 (2.79)	14.58 (5.75)	8.37 (5.78)	11.75 (8.10)	Mixed exercise	16	5/30 min	Social conversation	Depressive symptoms
Williams et al, ⁶⁴ 2008 (supervised walking)	17	12	CSDD	12.18 (5.00)	14.58 (5.75)	9.68 (6.57)	11.75 (8.10)	Aerobic exercise	16	5/30 min	Social conversation	Depressive symptoms

Note. BDI=Beck Depression Inventory. CES=Centre for Epidemiologic Studies Depression. CIS=Clinical Interview Schedule. CSDD=Cornel Scale for Depression in Dementia. DACL=Depression Adjective Check Lists. DASS=Depression Anxiety Stress Scale. DSSS=Depression Somatic Symptom scale. GDS=Geriatric Depression Scale. HAMD=Hamilton Depression Scale. MADRS=Montgomery-Asberg Depression Rating Scale. MDD=Major Depressive Disorder. MMPI=Minnesota Multiphasic Personality Inventory. PHQ-9=Patient Health Questionnaire. POMS=Profile of Mood States. TGDS=Thai Geriatric Depression Scale. SDS=Severity of Dependence Scale. HRSD=Hamilton Rating Scale for Depression. DACL=Depression Adjective Checklist. SIGMA=screening tool for the assessment and design of human-centered work activities. Usual care=no treatment but including psychiatric, pharmaco-, and psychotherapeutic treatment if required. Mixed exercise=aerobic and resistance exercise. Studies with two exercise groups were compared to the same control group. In case of more than one outcome, mean and SD of the first named outcome are reported. Primary outcome as indicated by authors or, if not indicated, rated by a clinician were included in the main analyses. For varying minutes per session, the average was used for calculations. Values are presented as mean changes with standard errors. Values are presented as least Square Means (95%CI). Calculation of SDs from confidence intervals.

Supplementary Table 2. List of excluded studies at full-text screening stage, with brief reasons

	Author	Reason for exclusion
1.	Abdelbasset et al, 2021	Non depressed
2.	Abedi et al, 2015	Non depressed
3.	Abrahao et al, 2015	Ineligible patient population
4.	Abrantes et al, 2017	Ineligible intervention
5.	Aider et al, 2014	Ineligible patient population
6.	Akandere et al, 2011	Non depressed
7.	Almeida et al, 2022	Ineligible intervention
8.	Alves et al, 2013	Non depressed
8.	Ansai et al, 2015	Non depressed
9.	Antunes et al, 2005	Non depressed
10.	Armstrong et al, 2004	Non depressed
11.	Bang et al, 2016	Non depressed
12.	Belvederri Murri et al, 2015	Medication
13.	Bernard, Ninot, Cyprien et al, 2015	Ineligible outcome
14.	Bernard, Ninot, Bernard et al, 2015	Non depressed
15.	Blumenthal et al, 1999	Medication
16.	Blumenthal et al, 2012	Non depressed
17.	Bolier et al, 2013	Ineligible intervention
18.	Bonnet, 2005	Ineligible intervention
19.	Bosscher, 1993	Ineligible comparator
20.	Boström et al, 2015	Non depressed
21.	Brinsley et al, 2022	Non depressed
21.	Brittle et al, 2009	Non depressed
22.	Brown et al, 2009	Non depressed
23.	Buettner, 2002	Non depressed
24.	Buschert et al, 2019	Ineligible comparator
25.	Callaghan et al, 2011	Ineligible comparator
26.	Carneiro et al, 2016	Non depressed
27.	Carta et al, 2022	Non depressed
28.	Carter et al. 2022	Ineligible age
29.	Chalder et al, 2012	Ineligible intervention
		To disting the second second
28.	Chan et al. 2012	Ineligible intervention
29. 30.	Chen et al, 2017 Chu et al, 2008	Non depressed Ineligible comparator
30.	Ciccolo et al, 2008	Ineligible intervention
31.	Conradsson et al, 2010	Non depressed
32.	Courneya et al, 2007	Ineligible patient population
33.	Craft et al, 2007	Ineligible comparator
33. 34.	de la Cerda et al, 2011	Medication
35.	de Lima et al, 2016	Non depressed
35. 36.	Dalgas et al, 2010	Ineligible patient population
30. 37.	Damush et al, 1999	Non depressed
31.	Damasii Ct ai, 1777	non depressed

38.	Deschamps et al, 2015	Ineligible comparator
39.	Dorscht et al, 2019	Ineligible comparator
40.	Dunn et al, 2002	No control group
41.	Dunn et al, 2005	Ineligible comparator
42.	Ellard et al, 2014	Non depressed
43.	Euteneuer et al, 2017	Ineligible intervention
44.	Eyigor et al, 2010	Ineligible comparator
45.	Fang et al, 2013	Ineligible comparator
46.	Foley et al, 2008	Ineligible comparator
47.	Forsyth et al, 2015	Ineligible patient population
48.	Geliebter et al, 1997	Non depressed
49.	Gerber et al, 2013	Non depressed
50.	Gerber et al, 2020	Ineligible comparator
51.	Goldfield et al, 2015	Ineligible patient population
52.	Greer et al, 2015	No control group
53.	Guifeng et al, 2015	Ineligible comparator
54.	Gujral et al, 2019	Medication
55.	Häkkinen et al, 2001	Ineligible patient population
56.	Hanssen et al, 2018	Ineligible comparator
57.	Haussleiter et al, 2020	Ineligible comparator
58.	He et al, 2022	Ineligible comparator
58.	Helgadottir et al, 2018	Secondary data
59.	Herman et al, 2002	Duplicate
60.	Herring et al, 2011	Ineligible patient population
61.	Hess-Homeier, 1981	Ineligible intervention
62.	Ho et al, 2014	Ineligible comparator
63.	Hoffmann et al, 2008	Duplicate
64.	Hoffmann et al, 2010	Ineligible patient population
65.	Holmgren et al, 2010	Non depressed
66.	Huipeng et al, 2013	Ineligible comparator
67.	Imboden et al, 2019	Ineligible comparator
68.	Isaksen et al, 2016	Non depressed
69.	Jaggers et al, 2015	Non depressed
70.	Jin et al, 2019	Non depressed
71.	Jinchun et al, 2015	Ineligible comparator
72.	Kahl et al, 2015	Ineligible outcome
73.	Karahan et al, 2017	Ineligible patient population
74.	Karg et al, 2020	Ineligible comparator
75.	Kekäläinen et al, 2018	Non depressed
76.	Kerling et al, 2015	Ineligible comparator
77.	Kerr et al, 2008	Non depressed
78.	Kerse et al, 2010	Non depressed
79.	Kim et al, 2019	Non depressed
80.	Klein et al, 1985	Ineligible comparator
81.	Knapen et al, 2003	Ineligible patient population
82.	Knubben et al, 2007	Ineligible intervention
83.	Kraepelien et al, 2015	Secondary data
84.	Kratz et al, 2014	Ineligible intervention

85.	Krogh et al, 2007	Ineligible comparator
86.	Krogh et al, 2009	Ineligible comparator
87.	Krogh et al, 2012	Ineligible comparator
88.	Krogh et al, 2013	Ineligible outcome
89.	Kruisdijk et al, 2012	Ineligible patient population
	Kruisdijk et al, 2019	Ineligible patient population
91.	Kruisdijk et al, 2020	Ineligible patient population
92.	Lau et al, 2004	Ineligible patient population
93.	Le Cheminant et al, 2014	Non depressed
94.	Legrand et al, 2007	Medication
95.	Legrand et al, 2015	Medication
96.	Levinger et al, 2011	Non depressed
97.	Li et al, 2019	Ineligible intervention
98.	Lincoln et al, 2011	Ineligible patient population
99.	Lopez-Torres Hidalgo et al, 2019	No RCT
100.	Mailey et al, 2010	Ineligible patient population
101.	Majumder et al, 2015	Ineligible patient population
102.	Martins et al, 2011	Non depressed
103.	Martinsen et al, 1985	Ineligible comparator
104.	Martiny et al, 2015	Ineligible comparator
105.	Mata et al, 2012	Non depressed
106.	Matthews et al, 2011	Non depressed
107.	Mendham et al, 2021	Non depressed
108.	Meyer et al, 2022	Ineligible intervention
108.	Midtgaard et al, 2012	No control group
109.	Moraes et al, 2022	Ineligible comparator
109.	Nasstasia et al, 2019	Ineligible patient population
110.	Naumann et al, 2020	Ineligible comparator
111.	Neidig et al, 2003	Non depressed
	Neviani et al, 2017	Secondary data
113.	Ng et al, 2017	Non depressed
114.	Niederer et al, 2017	Ineligible comparator
115.	Nordbrandt et al, 2015	Non depressed
116.	Norvell et al, 1993	Non depressed
117.	Nyberg et al, 2015	Ineligible patient population
118.	Oeland et al, 2010	Ineligible patient population
119.	Ökzan et al, 2020	Non depressed
120.	Olson et al, 2017	Ineligible comparator
121.	O'Reilly et al, 1999	Non depressed
122.	Palmer et al, 1995	Non depressed
123.	Patten et al, 2017	Ineligible intervention
124.	Payne et al, 2008	Non depressed
125.	Penninx et al, 2002	Non depressed
126.	Pentecost et al, 2015	Ineligible intervention
127.	Pereira et al, 2013	Ineligible comparator
128.	Perna et al, 2010	Non depressed
129.	Peterson et al, 2014	Non depressed
130.	Philippot et al, 2022	Ineligible comparator

130. Pibernik-Okanovic et al, 2011 Ineligible patient population 131. Piette et al, 2011 Non depressed 132. Porter et al, 2012 Non depressed 133. Puterman et al, 2014 Non depressed 134. Putiri et al, 2014 Non depressed 135. Prakhinkit et al, 2015 Non depressed 136. Rantakokko et al, 2015 Non depressed 137. Razazian et al, 2016 Non depressed 138. Reuter, 1984 Ineligible intervention 139. Rueter, 1980 Ineligible comparator 140. Sadeghi et al, 2016 Medication 141. Salehi et al, 2016 Medication 142. Sarsan et al, 2006 Non depressed 143. Schmitter et al, 2020 Study protocol 144. Scholz et al, 2006 Non depressed 145. Sherwood et al, 2016 Ineligible outcome 146. Singh et al, 2001 Secondary data 147. Siqueira et al, 2011 Non depressed 148. Sparrow et al, 2011 Non depressed 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 Ineligible intervention 152. Tapps et al, 2013 Non depressed 153. Teychenne et al, 2021 Ineligible patient population 155. Toni et al, 2016 Secondary data 156. Trivedi et al, 2011 Ineligible comparator 157. Van der Kooi et al, 2007 Ineligible patient population 158. Van der Waerden et al, 2013 Non depressed 159. Vankova et al, 2014 Non depressed 160. Verrusio et al, 2014 Non depressed 161. Vieira et al, 2018 Non depressed 162. Vizza et al, 2016 Ineligible intervention 163. Wang et al, 2021 Ineligible comparator 164. Zanuso et al, 2012 Ineligible patient population 165. Zeibig et al, 2021 Ineligible intervention 166. Zeng et al, 2020 Ineligible patient population 167. Von depressed 168. Zeibig et al, 2021 Ineligible intervention 169. Vercausio et al, 2011 Ineligible intervention 160. Vercausio et al, 2014 Ineligible intervention 161. Vieira et al, 2016 Ineligible patient population 162. Vizza et al, 2016 Ineligible patient population 163. Wang et al, 2020 Ineligible patient population 164. Zenuso et al, 2021 Ineligible intervention			
132. Porter et al, 2011 133. Puterman et al, 2021 134. Putri et al, 2012 135. Prakhinkit et al, 2015 136. Rantakokko et al, 2015 137. Razazian et al, 2016 138. Reuter, 1980 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2006 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Richardson, Himle et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 154. Teychenne et al, 2021 155. Toni et al, 2014 160. Verrusio et al, 2014 160. Verrusio et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2017 164. Zanuso et al, 2017 164. Zanuso et al, 2017 165. Zeibig et al, 2012 166. Zeibig et al, 2017 166. Zeibig et al, 2021 Ineligible patient population 167. Von depressed 168. Non depressed 179. Non depressed 180. Non depressed		et al, 2011	Ineligible patient population
133. Puterman et al, 2021 134. Putiri et al, 2012 135. Prakhinkit et al, 2015 136. Rantakokko et al, 2015 137. Razazian et al, 2016 138. Reuter, 1984 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2011 148. Sparrow et al, 2011 149. Steiner, Richardson, Himle et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Tapps et al, 2013 152. Tapps et al, 2011 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2014 160. Verrusio et al, 2018 162. Vizza et al, 2018 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2012 165. Zeibig et al, 2021 165. Zeibig et al, 2021 165. Zeibig et al, 2021 Ineligible patient population Non depressed Ineligible intervention	· · · · · · · · · · · · · · · · · · ·		•
134. Putiri et al, 2012 135. Prakhinkit et al, 2014 136. Rantakokko et al, 2015 137. Razazian et al, 2016 138. Reuter, 1984 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 154. Teychenne et al, 2011 155. Toni et al, 2016 156. Trivedi et al, 2017 157. Van der Kooi et al, 2014 161. Vieira et al, 2018 162. Vieira et al, 2018 163. Wang et al, 2017 164. Zanuso et al, 2017 164. Zanuso et al, 2017 165. Zeibig et al, 2012 166. Zeibig et al, 2012 166. Zeibig et al, 2012 166. Zeibig et al, 2017 167. Zeibig et al, 2017 168. Van der poulation 180. control group 180. Non depressed 180. Non depressed 181. Non depressed 182. Van der Waerden et al, 2013 183. Van der Waerden et al, 2014 184. Sparrow et al, 2014 185. Van der Waerden et al, 2015 186. Varnova et al, 2014 187. Varnova et al, 2014 188. Van der Waerden et al, 2013 189. Van der Waerden et al, 2013 189. Van der Waerden et al, 2014 189. Varnova et al, 2014 189. Varnova et al, 2018 189. Van der Waerden et al, 2019 189. Van der Waerden et al, 2013 189. Van der Waerden et al, 2014 189. Varnova et al, 2018 189. Van der Waerden et al, 2019 189. Van der Waerden et al, 2010 189. Van der Waerden et al, 2011 189. Van der Waerden et al, 2013 189. Van der Waerden et al, 2014 189. Van der Waerden et al, 2015 189. Van der Waerden et al, 2016 189. Van der Waerden et al, 2017 189. Van der Waerden et al, 2018 189. Van der Waerden et al, 2019 189. Van	·		•
135. Prakhinkit et al, 2014 136. Rantakokko et al, 2015 137. Razazian et al, 2016 138. Reuter, 1980 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salchi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 154. Teychenne et al, 2021 155. Toni et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Zanuso et al, 2017 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2012 166. Zeibig et al, 2012 166. Zeibig et al, 2021 167. Zeibig et al, 2021 168. Zeibig et al, 2021	· · · · · · · · · · · · · · · · · · ·	.1	•
136. Rantakokko et al, 2015 137. Razazian et al, 2016 138. Reuter, 1984 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2016 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2011 148. Sparrow et al, 2011 149. Steiner, Richardson, Himle et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2014 160. Verhoeven et al, 2018 161. Vieira et al, 2018 162. Zanuso et al, 2017 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2012 166. Zeibig et al, 2021 166. Zeibig et al, 2017 167. Van der Rooi et al, 2017 168. Zanuso et al, 2017 169. Zeibig et al, 2021 160. Vendeven et al, 2017 160. Vendeven et al, 2017 161. Vieira et al, 2018 162. Zeibig et al, 2021 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2021 166. Trivedi et al, 2011 167. Van der Rooi et al, 2014 168. Vander Varefue et al, 2018 169. Varesed 160. Verrousio et al, 2014 160. Verrousio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2017 165. Zeibig et al, 2021 165. Zeibig et al, 2021	134. Putiri et al, 2012		Ineligible patient population
137. Razazian et al, 2016 138. Reuter, 1984 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2011 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2011 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verrusio et al, 2018 161. Vieira et al, 2018 162. Zapetidou et al, 2017 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 166. Zeibig et al, 2012 166. Zeibig et al, 2012 166. Zeibig et al, 2011 167. Zanetidou et al, 2017 168. Zaeibig et al, 2011 169. Zeibig et al, 2011 160. Verhoeven et al, 2018 161. Vieira et al, 2018 162. Zaeibig et al, 2011 163. Wang et al, 2012 164. Zanuso et al, 2011 165. Zeibig et al, 2021 166. Zeibig et al, 2021 166. Zeibig et al, 2021 167. Zeibig et al, 2021 168. Zeibig et al, 2021 169. Verhouven et al, 2017 160. Verhouven et al, 2018 160. Verhouven et al, 2018 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2017 165. Zeibig et al, 2021 166. Zeibig et al, 2021 167. Van depressed 168. Non depressed 169. Verhouven et al, 2019 189. Vankova et al, 2019 189. Vankova et al, 2018 189. Vankova et al, 2019 189. Vankova et al, 2010 189. Vankova et al, 2010 189. Vankova et al, 2010 189. Vankova	135. Prakhinkit et al, 20	14	No control group
138. Reuter, 1984 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salchi et al, 2016 142. Sarsan et al, 2020 143. Schmitter et al, 2020 144. Scholz et al, 2016 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 154. Teychenne et al, 2016 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2012 164. Zanuso et al, 2012 165. Zeibig et al, 2021 Ineligible patient population Secondary data Non depressed	-		-
139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2016 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2014 160. Verhoeven et al, 2018 162. Vizza et al, 2018 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2012 Ineligible patient population Secondary data Non depressed Non depressed Non depressed Non depressed Ineligible patient population Non depressed Non depressed Ineligible comparator Ineligible patient population Non depressed Non depressed Ineligible patient population Non depressed Non depressed Non depressed Ineligible patient population Non depressed Non depressed Non depressed Ineligible patient population Non depressed	137. Razazian et al, 2010	6	Non depressed
140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2011 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verrousio et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2012 164. Zanuso et al, 2012 165. Zeibig et al, 2012 166. Zeibig et al, 2021 Ineligible patient population Ineligible intervention Non depressed Ineligible comparator Ineligible intervention Non depressed Ineligible intervention Non depressed Ineligible intervention Non depressed Ineligible intervention Non depressed Ineligible patient population Non depressed Ineligible intervention Non depressed Ineligible patient population	138. Reuter, 1984		Ineligible intervention
141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2019 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2014 158. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2012 165. Zeibig et al, 2012 166. Zeibig et al, 2021 Ineligible patient population Secondary data Ineligible comparator Ineligible intervention Non depressed Ineligible intervention Secondary data Ineligible patient population Non depressed Ineligible intervention Non depressed Ineligible intervention Non depressed	139. Rueter, 1980		Ineligible comparator
142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2017 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2012 Ineligible intervention Non depressed Non depressed Non depressed Non depressed Non depressed Non depressed Ineligible patient population Non depressed Ineligible intervention Non depressed Ineligible patient population Non depressed Ineligible patient population Non depressed Ineligible patient population Non depressed	140. Sadeghi et al, 2016		
143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2018 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2012 166. Ineligible patient population 167. Van der Kooi et al, 2014 168. Vizza et al, 2018 169. Vizza et al, 2019 160. Verrusio et al, 2019 161. Vieira et al, 2019 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 166. Ineligible patient population 167. Secondary data 168. Non depressed 169. Vizza et al, 2016 169. Vizza et al, 2016 160. Vieira et al, 2017 160. Vieira et al, 2019 161. Vieira et al, 2019 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 165. Ineligible patient population 166. Vieira et al, 2019 167. Vieira et al, 2019 168. Vizza et al, 2019 169. Vizza et al, 2019 169. Vizza et al, 2019 160. Vieira et al, 2019 160. Vieira et al, 2019 161. Vieira et al, 2019 162. Vizza et al, 2019 163. Zanetidou et al, 2019 164. Zanuso et al, 2019 165. Zeibig et al, 2021	141. Salehi et al, 2016		Medication
144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2013 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2012 166. Teiligible patient population 167. Van der Kooi et al, 2014 168. Vizza et al, 2016 169. Vizza et al, 2016 160. Verrusio et al, 2017 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 165. Zeibig et al, 2021 166. Ineligible patient population 167. Van depressed 168. Vizza et al, 2016 169. Verrusio et al, 2017 160. Verrusio et al, 2017 160. Verrusio et al, 2019 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 165. Ineligible patient population 167. Vieira et al, 2018 168. Vizza et al, 2019 169. Vizza et al, 2019 160. Verrusio et al, 2019 161. Vieira et al, 2019 162. Vizza et al, 2016 163. Vang et al, 2021 164. Zanuso et al, 2011 165. Zeibig et al, 2021	142. Sarsan et al, 2006		Non depressed
145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2017 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Vernusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2012 166. Ineligible outcome Secondary data 167. Medication 189. Medication 180. Medication 180. Medication 180. Medication 180. Medication 180. Non depressed 181. Non depressed 182. Vizza et al, 2014 183. Non depressed 184. Non depressed 185. Zeibig et al, 2017 186. Secondary data 186. Non depressed 187. Non depressed 188. Non depressed 189. Non d	143. Schmitter et al, 202	20	Study protocol
146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2012 165. Zeibig et al, 2021 166. Secondary data 167. Ineligible patient population 178. Non depressed 189. Non depressed 199. Ineligible comparator 199. Ineligible comparator 199. Ineligible intervention 199. Non depressed 199. Verrusio et al, 2014 199. Ineligible intervention 199. Non depressed 199. Verrusio et al, 2014 199. Non depressed 199. Non depres	144. Scholz et al, 2006		Non depressed
147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2012 166. Zeibig et al, 2012 167. Van der Kooi et al, 2018 168. Vizza et al, 2018 169. Vizza et al, 2019 160. Vernusio et al, 2019 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 166. Trivedi et al, 2012 167. Vander Wander	145. Sherwood et al, 201	16	Ineligible outcome
148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2012 166. Teivedi et al, 2017 167. Van der Waerden et al, 2018 168. Vander Waerden et al, 2019 169. Verrusio et al, 2014 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible intervention Secondary data Non depressed Ineligible patient population	146. Singh et al, 2001		Secondary data
149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2012 166. Zeibig et al, 2012 167. Van der Waerden et al, 2018 168. Van der Waerden et al, 2019 169. Verrusio et al, 2018 160. Verrusio et al, 2018 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 166. Veressed 167. Vieira et al, 2019 170. Vieira et al, 2019 180. Vizza et al, 2016 180. Vizza et al, 201	147. Siqueira et al, 2016		Medication
150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Ineligible intervention Ineligible intervention Non depressed Ineligible comparator Ineligible intervention Non depressed Ineligible intervention Non depressed Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Non depressed Ineligible patient population	148. Sparrow et al, 2011		Non depressed
Ineligible intervention 152. Tapps et al, 2013 Non depressed 153. Teychenne et al, 2019 Non depressed 154. Teychenne et al, 2021 Ineligible patient population 155. Toni et al, 2016 Secondary data 156. Trivedi et al, 2011 Ineligible comparator 157. Van der Kooi et al, 2007 Ineligible patient population 158. Van der Waerden et al, 2013 Non depressed 159. Vankova et al, 2014 Non depressed 160. Verhoeven et al. 2022 Ineligible comparator Ineligible comparator Ineligible intervention Non depressed Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible intervention Ineligible intervention Ineligible intervention Ineligible patient population	149. Steiner, Bigatti, An	g et al, 2015	Non depressed
152. Tapps et al, 2013 Non depressed 153. Teychenne et al, 2021 Ineligible patient population 155. Toni et al, 2016 Secondary data 156. Trivedi et al, 2011 Ineligible comparator 157. Van der Kooi et al, 2007 Ineligible patient population Non depressed 158. Van der Waerden et al, 2013 Non depressed 159. Vankova et al, 2014 Non depressed 160. Verhoeven et al. 2022 Ineligible comparator Ineligible comparator Ineligible comparator Ineligible patient population Non depressed Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible intervention Non depressed Ineligible intervention Secondary data Ineligible intervention Non depressed Ineligible intervention Secondary data Non depressed Ineligible patient population Ineligible intervention Ineligible intervention Ineligible intervention Ineligible patient population	150. Steiner, Richardson	n, Himle et al, 2015	Ineligible intervention
153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al. 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2012 165. Zeibig et al, 2021 Non depressed Non depressed Ineligible comparator Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible patient population Ineligible intervention Ineligible intervention Ineligible patient population Ineligible patient population Ineligible patient population	151. Ström et al, 2013		Ineligible intervention
154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al. 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Ineligible patient population Ineligible comparator Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible patient population Ineligible patient population Ineligible intervention	152. Tapps et al, 2013		Non depressed
155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al. 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Ineligible comparator Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible intervention Ineligible patient population Ineligible intervention Ineligible patient population Ineligible patient population Ineligible patient population	153. Teychenne et al, 20	19	Non depressed
156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al. 2022 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Ineligible comparator Ineligible comparator Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible intervention Ineligible intervention Ineligible patient population Ineligible intervention Ineligible patient population	154. Teychenne et al, 20	21	Ineligible patient population
157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al. 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Ineligible patient population Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible intervention Ineligible patient population Ineligible patient population	155. Toni et al, 2016		Secondary data
158. Van der Waerden et al, 2013 Non depressed 159. Vankova et al, 2014 Non depressed 160. Verhoeven et al. 2022 Ineligible comparator 160. Verrusio et al, 2014 Ineligible intervention Non depressed 161. Vieira et al, 2018 Non depressed 162. Vizza et al, 2016 Ineligible patient population 163. Wang et al, 2022 Ineligible intervention 164. Zanuso et al, 2017 Secondary data Non depressed 165. Zeibig et al, 2021 Ineligible patient population	156. Trivedi et al, 2011		Ineligible comparator
159. Vankova et al, 2014 160. Verhoeven et al. 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Non depressed Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible patient population	157. Van der Kooi et al,	2007	Ineligible patient population
160.Verhoeven et al. 2022Ineligible comparator160.Verrusio et al, 2014Ineligible intervention161.Vieira et al, 2018Non depressed162.Vizza et al, 2016Ineligible patient population163.Wang et al, 2022Ineligible intervention163.Zanetidou et al, 2017Secondary data164.Zanuso et al, 2012Non depressed165.Zeibig et al, 2021Ineligible patient population	158. Van der Waerden e	t al, 2013	
160. Verrusio et al, 2014Ineligible intervention161. Vieira et al, 2018Non depressed162. Vizza et al, 2016Ineligible patient population163. Wang et al, 2022Ineligible intervention163. Zanetidou et al, 2017Secondary data164. Zanuso et al, 2012Non depressed165. Zeibig et al, 2021Ineligible patient population	159. Vankova et al, 2014	4	•
161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2021 Non depressed Non depressed Non depressed Non depressed Ineligible patient population	160. Verhoeven et al. 20	22	-
 162. Vizza et al, 2016 Ineligible patient population 163. Wang et al, 2022 Ineligible intervention 163. Zanetidou et al, 2017 Secondary data 164. Zanuso et al, 2012 Non depressed 165. Zeibig et al, 2021 Ineligible patient population 	•	1	
 163. Wang et al, 2022 Ineligible intervention 163. Zanetidou et al, 2017 Secondary data 164. Zanuso et al, 2012 Non depressed 165. Zeibig et al, 2021 Ineligible patient population 			
 163. Zanetidou et al, 2017 Secondary data 164. Zanuso et al, 2012 Non depressed 165. Zeibig et al, 2021 Ineligible patient population 	-		
 164. Zanuso et al, 2012 165. Zeibig et al, 2021 Non depressed Ineligible patient population 			_
165. Zeibig et al, 2021 Ineligible patient population		17	
	·		-
166. Zeng et al, 2020 Ineligible intervention	_		
	166. Zeng et al, 2020		Ineligible intervention

Note. Of the k=218 papers reviewed in full-text, k=177 were excluded.

Study	Intervention group	Comparator	D1	D2	D3	D4	D5	Overall
Abdelbasset et al, ⁴² 2019	Aerobic exercise	Usual care	!	+	+	+	+	!
Blumenthal et al, ⁶³ 2007	Aerobic exercise	Placebo	+	•	+	+	+	+
Brenes et al, 43 2007	Mixed exercise	Usual care	1	+	+		!	-
Carneiro et al, ⁶⁴ 2015	Usual care*aerobic exercise	Usual care	•	1	+		!	-
Chau et al, ⁶⁵ 2020	Mixed exercise	Wait-list	•	+	+	+	+	+
Cheung et al, 48 2018	Aerobic exercise	Usual care	•	+	+	+	+	+
Danielsson et al, ⁶⁷ 2014	Usual care*aerobic exercise	Usual care	•	+	+	+	+	+
Doose et al, ⁶⁸ 2015	Aerobic exercise	Wait-list	!	+	+		+	-
Doyne et al, 44 1987	Mixed exercise	Wait-list	+	+		+	•	
Epstein, ⁶⁹ 1986	Aerobic exercise	Wait-list	!		!	!	!	-
Gao et al, ⁴⁵ 2016	Aerobic exercise	Usual care	•	1	+	!	+	!
Gary et al, 70 2010	Aerobic exercise	Usual care	!	1	+	+	+	!
Hallgren et al, 46 2015	Mixed exercise	Usual care	•	+	+	+	+	+
Hemat-Far et al, ⁴⁷ 2012	Aerobic exercise	Usual care	-	1	+		+	-

Huang et al, 48 2015	Mixed exercise	Usual care	• •	+	!	+	!
La Rocque et al, ⁷¹ 2020	Aerobic exercise	Wait-list	+ +	+	+	+	+
Legrand et al, ⁴⁹ 2014	Aerobic exercise	Wait-list	+ +	+		!	-
Lok et al, ⁵⁰ 2017	Aerobic exercise	Wait-list	! +	+	-	-	-
Makizako et al, ⁵² 2019	Mixed exercise	Health education	• •	•	!	+	!
Mather et al,41 2002	Mixed exercise	Health education	! 4	+	!	+	!
McNeil et al, ⁵¹ 1991	Aerobic exercise	Wait-list	1 4	+	-	!	-
Mota-Pereira et al, ⁷² 2011	Usual care*aerobic exercise	Usual care	!	!	+	+	-
Mutrie, ⁵³ 1986	Mixed exercise	Wait-list	• •	+		-	-
Mutrie, ⁵³ 1986 Nabkasorn et al, ⁵⁴ 2006	Mixed exercise Aerobic exercise	Wait-list Usual care	• • • • • • • • • • • • • • • • • • •	1		1	-
			• • • • • • • • • • • • • • • • • • •	•		!	- - !
Nabkasorn et al, ⁵⁴ 2006 Oertel-Knöchel et al, ⁷³	Aerobic exercise	Usual care	+		1	!	!
Nabkasorn et al, ⁵⁴ 2006 Oertel-Knöchel et al, ⁷³ 2014	Aerobic exercise Aerobic exercise	Usual care Wait-list		•	1 +		!
Nabkasorn et al, ⁵⁴ 2006 Oertel-Knöchel et al, ⁷³ 2014 Orth, ⁵⁵ 1979	Aerobic exercise Aerobic exercise Aerobic exercise	Usual care Wait-list Self-monitoring	•	•		•	
Nabkasorn et al, ⁵⁴ 2006 Oertel-Knöchel et al, ⁷³ 2014 Orth, ⁵⁵ 1979 Pfaff et al, ⁶² 2014	Aerobic exercise Aerobic exercise Aerobic exercise Mixed exercise	Usual care Wait-list Self-monitoring Usual care	• •	•		•	

Schneider et al, ⁷⁶ 2016	Mixed exercise	Usual care + + + +	+ +
Schuch et al, ⁷⁷ 2015	Aerobic exercise	Usual care + + + +	+ +
Setaro, ⁵⁷ 1985	Aerobic exercise	Usual care + + + +	+ +
Shahidi et al, ⁵⁸ 2011	Aerobic exercise	Unclear !	!
Sims et al, ⁵⁹ 2006	Resistance exercise	Advise for activity + + + !	<u> </u>
Sims et al, ⁶⁰ 2009	Resistance exercise	Wait-list + + !	<u> </u>
Singh et al, 78 1997	Resistance exercise	Health education	!
Singh et al, ⁷⁹ 2005	Resistance exercise	Usual care + + + +	+ +
Veale et al, 80 1992	Aerobic exercise	Usual care - !	!
Vieira et al,81 2007	Aerobic exercise	Usual care ! + +	!
Williams et al, ⁶¹ 2008	Mixed exercise	Social conversation + + + +	

Note. += low risk, != some concerns, -= high risk, D1 = Randomisation process, D2 = Deviations from the intended interventions, D3 = Missing outcome data, D4 = Measurement of the outcome, D5 = Selection of the reported result.

Author, year, country	Age (mean	or range)	Gender (%	(females)	Antidepress (% taking)	sant use	Thesis or Peer- reviewed article
	Exercise	Control	Exercise	Control	Exercise	Control	
Abdelbasset et al, ⁴² 2019, Saudi-Arabia Blumenthal et al, ⁶³	52.60	52.90	31.00	26.00	N/A	N/A	Peer-reviewed
2007, USA	52.00	52.00	75.00	77.00	0	0	Peer-reviewed
Brenes et al, ⁴³ 2007, USA	73.50	73.90	64.00	50.00	0	0	Peer-reviewed
Carneiro et al, ⁶⁴ 2015, Portugal	52.78	47.80	100	100	100	100	Peer-reviewed
Chau et al, ⁶⁵ 2020, Hong Kong	N/A	N/A	74.00	86.00	83.00	83.00	Peer-reviewed
Cheung et al, 48 2018, Hong Kong/ China	47.40	48.10	88.20	70.60	94.12	88.24	Peer-reviewed
Danielsson et al, ⁶⁷ 2014, Sweden	44.70	46.30	73.00	80.00	100	100	Peer-reviewed
Doose et al, ⁶⁸ 2015, Germany	46.10	51.25	60.00	68.80	50.00	75.00	Peer-reviewed
Doyne et al, ⁴⁴ 1987, USA	28.58	29.46	100	100	0	0	Peer-reviewed
Epstein, ⁶⁹ 1986, USA	24-60	24-60	N/A	N/A	N/A	N/A	Thesis
Gao et al, ⁴⁵ 2016, China	54.50	53.50	100	100	0	0	Peer-reviewed
Gary et al, ⁷⁰ 2010, USA	30-70	30-70	N/A	N/A	N/A	N/A	Peer-reviewed

Hallgren et al, 46 2015,	18-71	18-71	N/A	N/A	31.00	24.00	Peer-reviewed
Sweden	10 /1	10 /1	1,771	1,771	21.00	200	100110110110
Hemat-Far et al, ⁴⁷ 2012, Iran	18-25	18-25	100	100	N/A	N/A	Peer-reviewed
Huang et al, ⁴⁸ 2015, Taiwan	76.42	75.85	57.90	55.00	0	0	Peer-reviewed
La Rocque et al, ⁷¹ 2020, Canada	34.85	29.40	100	100	20.00	46.70	Peer-reviewed
Legrand et al, ⁴⁹ 2014, France	19 - 30	19-30	100	100	0	0	Peer-reviewed
Lok et al, ⁵⁰ 2017, Turkey	≥65.00	≥65.00	42.50	47.50	0	0	Peer-reviewed
Makizako et al, ⁵² 2019, Japan	73.10	73.00	53.30	51.70	0	0	Peer-reviewed
Mather et al, ⁴¹ 2002, United Kingdom	63.70	66.20	84.00	53.00	100	100	Peer-reviewed
McNeil et al, ⁵¹ 1991, Canada	N/A	N/A	N/A	N/A	0	0	Peer-reviewed
Mota-Pereira et al, ⁷² 2011, Portugal	48.68	45.33	57.90	80.00	100	100	Peer-reviewed
Mutrie, ⁵³ 1986, United Kingdom	45.70	41.10	N/A	N/A	0	0	Thesis
Nabkasorn et al, ⁵⁴ 2006, Thailand	18.70	18.80	100	100	0	0	Peer-reviewed
Oertel-Knöchel et al, ⁷³ 2014, Germany	36.60	42.20	50.00	37.50	100	100	Peer-reviewed
Orth, ⁵⁵ 1979, USA	N/A	N/A	N/A	N/A	N/A	N/A	Thesis
Pfaff et al, ⁶² 2014, Australia	61.20	60.70	62.00	64.10	60.20	47.80	Peer-reviewed

Pilu et al, 74 2007, Italy	40-60	40-60	100	100	100	100	Peer-reviewed
Prakhinkit et al, ⁵⁶ 2014, Thailand	74.80	81.00	100	100	0	0	Peer-reviewed
Roy et al, ⁷⁵ 2018, India	31.10	32.90	100	100	N/A	N/A	Peer-reviewed
Schneider et al, ⁷⁶ 2016, USA	53.30	53.60	100	100	N/A	N/A	Peer-reviewed
Schuch et al, ⁷⁷ 2015, Brazil	38.84	41.76	72.00	76.00	84.00	96.00	Peer-reviewed
Setaro, ⁵⁷ 1985, USA	N/A	N/A	N/A	N/A	N/A	N/A	Thesis
Shahidi et al, ⁵⁸ 2011, Iran	65.70	68.40	100	100	N/A	N/A	Peer-reviewed
Sims et al, ⁵⁹ 2006, Australia	75.25	74.30	85.71	50.00	0	0	Peer-reviewed
Sims et al, ⁶⁰ 2009, Australia	67.95	66.27	39.00	41.00	0	0	Peer-reviewed
Singh et al, ⁷⁸ 1997, USA	70.00	72.00	70.60	53.30	0	0	Peer-reviewed
Singh et al, ⁷⁹ 2005, Australia	69.00	69.00	55.00	50.00	0	0	Peer-reviewed
Veale et al, ⁸⁰ 1992, United Kingdom	19-58	19-58	N/A	N/A	45.00	34.00	Peer-reviewed
Vieira et al, ⁸¹ 2007, Brazil	N/A	N/A	100	100	100	100	Peer-reviewed
Williams et al, 61 2008, USA	/1-101	71-101	N/A	N/A	36.00	36.00	Peer-reviewed

Note. Not available (N/A).

Supplementary Table 5. Characteristics of Included Studies

Study	Comorbidities	Group exercise	Setting	Intensity	Supervised	Type of supervision
Abdelbasset et al, ⁴² 2019	Yes	Unclear	Outpatient	Moderate	Supervised	Unclear
Blumenthal et al, ⁶³ 2007 (supervised exercise)	No	Yes	Outpatient	Vigorous	Supervised	Unclear
Blumenthal et al, ⁶³ 2007 (homebased exercise)	No	No	Outpatient	Vigorous	Unsupervised	None
Brenes et al, 43 2007	No	Yes	Outpatient	Unclear	Supervised	Exercise professional (certified ACSM exercise leader)
Carneiro et al, ⁶⁴ 2015	No	Yes	Outpatient	Moderate	Supervised	Exercise professional (physical training teacher)
Chau et al, ⁶⁵ 2020	No	Yes	Inpatient	Moderate	Supervised	Exercise professional (physiotherapist)
Cheung et al, ⁴⁸ 2018	No	No	Outpatient	Moderate	Supervised	Exercise professional (qualified personal trainer)
Danielsson et al, ⁶⁷ 2014	No	No	Outpatient	Vigorous	Supervised	Exercise professional (physiotherapist)
Doose et al, ⁶⁸ 2015	No	Yes	Outpatient	Light	Supervised	Other (teams of coaches and medical students)
Doyne et al, 44 1987	No	No	Outpatient	Vigorous	Supervised	Other (trained undergraduate exercise

(running condition)						monitors)
Doyne et al, ⁴⁴ 1987 (weightlifting)	No	No	Outpatient	Moderate	Supervised	Other (trained undergraduate exercise monitors)
Epstein, ⁶⁹ 1986	No	Yes	Outpatient	Moderate	Supervised	Other (clinical graduate students)
Gao et al, 45 2016	No	Yes	Outpatient	Moderate	Supervised	Exercise professional (professional coach and doctor)
Gary et al, ⁷⁰ 2010	Yes	No	Outpatient	Moderate	Unsupervised	None
Hallgren et al, ⁴⁶ 2015	No	Yes	Outpatient	Light to vigorous ^b	Supervised	N/A
Hemat-Far et al, ⁴⁷ 2012	No	Unclear	Outpatient	Moderate	Supervised	Other (researcher)
Huang et al, ⁴⁸ 2015	No	Yes	Outpatient	Moderate	Supervised	Exercise professional (trained physical fitness instructor)
La Rocque et al, ⁷¹ 2020	Yes	Yes	Outpatient	Moderate	Supervised	Exercise professional (professional exercise instructor)
Legrand et al, 49 2014	No	Yes	Outpatient	Moderate	Supervised	Exercise professional (certified zumba instructor)
Lok et al, ⁵⁰ 2017	Unclear	Yes	Outpatient	Moderate	Supervised	Other (researcher)
Makizako et al, ⁵² 2019	Yes	Yes	Outpatient	Moderate	Supervised	Exercise professional (trained instructors)
Mather et al,41 2002	No	Yes	Outpatient	Unclear	Supervised	Other (instructor)
McNeil et al, ⁵¹ 1991	No	No	Outpatient	Vigorous	66% supervised & 33% unsupervised ^c	Other (undergraduate psychology student)

Mota-Pereira et al, ⁷² 2011	No	No	Outpatient	Moderate	20% supervised & 80% unsupervised ^c	Exercise professional
Mutrie, ⁵³ 1986 (aerobic exercise)	No	Unclear	Outpatient	Moderate	Unsupervised	None
Mutrie, ⁵³ 1986 (strength & stretching)	No	Unclear	Outpatient	Vigorous	Unsupervised	None
Nabkasorn et al, ⁵⁴ 2006	No	Yes	Outpatient	Moderate	Supervised	Exercise professional (physical fitness instructor)
Oertel-Knöchel et al, ⁷³ 2014	No	Yes	Inpatient	Moderate	Supervised	Exercise professional (trained physical fitness instructor
Orth, ⁵⁵ 1979	No	Unclear	Outpatient	Moderate	Unsupervised	None
Pfaff et al, ⁶² 2014	No	No	Outpatient	Moderate to vigorous	Unsupervised	None
Pilu et al, ⁷⁴ 2007	No	Yes	Outpatient	Unclear	Supervised	Exercise professional (skilled instructor with isef (physical education) diploma, psychology degree and post-degree diploma in sport psychopathology (MS)
Prakhinkit et al, ⁵⁶ 2014 (traditional walking)	No	Unclear	Outpatient	Moderate	Supervised	Other (researcher)
Prakhinkit et al, ⁵⁶ 2014 (Buddhism walking)	No	Unclear	Outpatient	Moderate	Supervised	Other (researcher)
Roy et al, ⁷⁵ 2018	Unclear	Yes	Inpatient	Moderate	Supervised	Other (registered nurse)
Schneider et al, ⁷⁶ 2016	Yes	Yes ^a	Outpatient	Moderate	Supervised	Exercise professional (pilates/yoga

						instructor)
Schuch et al, ⁷⁷ 2015	No	No	Inpatients	Unclear	Supervised	Exercise professional (researcher and sport-scientist)
Setaro, ⁵⁷ 1985	No	Yes	Outpatient	Unclear	Supervised	Exercise professional (certified aerobic dance instructor)
Shahidi et al, ⁵⁸ 2011	No	Yes	Outpatient	Unclear	Unclear	Unclear
Sims et al, ⁵⁹ 2006	No	No	Outpatient	Vigorous	Supervised	Unclear
Sims et al, 60 2009	Yes	Yes	Outpatient	Vigorous	Supervised	Exercise professional (accredited fitness trainer)
Singh et al, 78 1997	No	Yes	Outpatient	Vigorous	Supervised	Other (researcher/principal investigator)
Singh et al, ⁷⁹ 2005 (high intensity)	No	Yes	Outpatient	Vigorous	Supervised	Unclear
Singh et al, ⁷⁹ 2005 (low intensity)	No	Yes	Outpatient	Light	Supervised	Unclear
Veale et al,80 1992	No	Yes	Outpatient	Unclear	Supervised	Unclear
Vieira et al,81 2007	No	Yes	Inpatient	Moderate	Supervised	Unclear
Williams et al, 61 2008 (mixed exercise)	Yes	No	Outpatient	Unclear	Supervised	Other (graduate nursing or physical therapy students)
Williams et al, ⁶¹ 2008 (supervised walking)	Yes	No	Outpatients	Unclear	Supervised	Other (graduate nursing or physical therapy students)
Vieira et al, 81 2007 Williams et al, 61 2008 (mixed exercise) Williams et al, 61 2008	No Yes Yes	Yes No	Inpatient Outpatient Outpatients	Moderate Unclear	Supervised Supervised	Unclear Other (graduate nursing or physical therapy students) Other (graduate nursing or physical

Note. Not available (N/A). American College of Sports Medicine (ACSM). ^aParticipants were asked to additionally train once a week at home. ^bParticipants were randomized to light, moderate, and vigorous intensity exercise. In the subgroup analysis, this study was rated as moderate. ^cStudy was rated as supervised in the subgroup analyses.

		Meta an	J 515			Heterogeneity	Trim and fill effect size	
	of RCTs						(95%CI) [adjusted studies]	
		SMD	95	5%CI	p- value	ie I ²		
Main analysis	19	-0.717	-1.01	-0.43	<.001	82.372	-0.897 (-1.219; -0.575) [3]	
Depression								
classification								
MDD^{a}	11	-0.567	-0.94	-0.20	.003	78.114	Unchanged	
Depressive symptoms	8	-0.951	-1.47	-0.43	<.001	87.373	-1.115 (-1.707; -0.523) [1]	
Type of control condition	1							
Usual care	12	-0.763	-1.13	-0.40	<.001	83.728	-0.973 (-1.403; -0.543) [2]	
Wait list	3	-1.315	-1.89	-0.74	<.001	46.548	-1.678 (-2.252; -1.105) [2]	
Health education	2	-0.107	-0.44	0.23	.528	0.000	N/A	
Intensity of exercise ^b								
Light	1	-0.293	-0.95	0.37	.383	0.000	N/A	
Moderate	13	-0.775	-1.17	-0.38	<.001	85.562	-0.977 (-1.422; -0.532) [2]	
Vigorous	4	-0.324	-0.61	-0.04	.028	28.767	-0.254 (-0.550; 0.043) [1, right of mean]	
Exercise type ^b							•	
Aerobic	12	-0.891	-1.32	-0.46	<.001	81.277	-1.254 (-1.760; -0.747) [4]	
Resistance	2	-0.508	-0.98	-0.04	.033	0.000	N/A	
Mixed ^c	7	-0.396	-0.79	-0.00	.049	84.939	Unchanged	
Group exercise ^b							-	
Yes	13	-0.646	-0.97	-0.38	<.001	80.129	Unchanged	
No	6	-0.330	-0.58	-0.08	.010	33.470	-0.205 (-0.474; 0.063) [2, right of mean]	
Supervision ^b								

Yes ^d	17	-0.769	-1.08	-0.46	<.001	82.500	-0.906 (-1.236; -0.576) [2]
No	4	-0.119	-0.34	0.10	.293	0.000	-0.098 (-0.308; 0.111) [2, right
_							of mean]
Type of supervision ^b							
Exercise professional	11	-0.830	-1.22	-0.45	<.001	74.192	Unchanged
Other professional/	1	-0.061	-0.49	0.36	.778	0.000	N/A
student							
Sample size							
intervention arm ^b							
n≥25	9	-0.516	-0.84	-0.19	.002	84.053	-0.576 (-0.890; -0.261) [1]
n<25	12	-0.801	-1.25	-0.35	<.001	76.648	-1.148 (-1.612; -0.683) [4]
n≥10	19	-0.665	-0.94	-0.39	<.001	83.059	Unchanged
n<10	2	-0.588	-1.52	0.34	.215	0.000	N/A

Note. See Supplement eTable 2, 3 and 4 for detailed categorization for each study. MDD=Major depressive Disorder; RCT=Randomized Controlled Trial, SMD=Standard mean difference. aIncluding 3 studies with MDD & Dysthymia 6,77,78 bData for a second intervention group within the same study were included for these analyses. Mixed exercise=aerobic and resistance exercise. Two studies were partly supervised, see Supplement Table 5.

Supplementary Table 7. Subgroup Analysis for Studies with MDD Diagnosis^a

Analysis	Numbe r of	Meta analysis				Heterogeneity	Trim and fill effect size (95% CI)	
	RCTs						[adjusted studies]	
	11015	SMD	95	% CI	p- value	I^2	[adjasted stadies]	
Main analysis MDD	20	-0.998	-1.39	-0.61	<.001	85.746	-1.167 (-1.591; -0.742) [2]	
Risk of bias								
Low risk of bias	9	-0.607	-1.03	-0.18	.005	82.240	-0.462 (-0.921; -0.003) [1,	
							right of mean]	
Some concerns	2	-0.300	-0.87	0.27	.302	0.000	N/A	
High risk of bias	9	-1.687	-2.53	-0.84	<.001	89.056	Unchanged	
Type of control condition	on							
Usual care	13	-0.762	-1.19	-0.34	<.001	81.767	-0.999 (-1.480; -0.518) [2]	
Wait list	5	-1.443	-1.82	-1.07	<.001	18.443	-1.606 (-2.017; -1.195) [2]	
Health education	1	-3.462	-4.56	-2.37	<.001	0.000	N/A	
Intensity of exercise ^b								
Light	2	-1.041	-2.53	0.45	.170	88.867	N/A	
Moderate	12	-1.012	-1.57	-0.45	<.001	86.889	-1.317 (-1.987; -0.639) [2]	
Vigorous	5	-0.881	-1.62	-0.15	.019	88.544	-1.152 (-2.039; -0.265) [1]	
Exercise type ^b								
Aerobic	15	-0.893	-1.29	-0.50	<.001	80.672	-1.084 (-1.535; -0.633) [2]	
Resistance	4	-1.354	-2.48	-0.23	.018	87.859	-1.752 (-3.010; -0.499) [1]	
Mixed ^c	3	-0.430	-1.62	0.77	.481	94.350	Unchanged	
Group exercise ^b							2	
Yes	15	-0.985	-1.44	-0.53	<.001	84.222	Unchanged	
No	7	-0.743	-1.29	-0.19	.008	85.582	-1.175 (-1.926; -0.424) [2]	
Supervision ^b							, , , , , , , , , , , , , , , , , , ,	
Yes	19	-1.066	-1.48	-0.66	<.001	84.441	-1.333 (-1.807; -0.860) [3]	
No	3	-0.110	-0.33	0.11	.334	0.000	-0.078 (-0.265; 0.108) [2,	

							right of mean]
Type of supervision ^b							
Exercise professional	10	-1.077	-1.64	-0.52	<.001	81.997	-1.450 (-2.037; -0.863) [3]
Other professional/	4	-1.664	-2.88	-0.45	.007	87.977	Unchanged
student							
Sample size							
intervention arm ^b							
n≥25	6	-0.444	-0.91	0.02	.061	86.212	-0.530 (-0.969; -0.090) [1]
n<25	16	-1.144	-1.63	-0.66	<.001	82.403	-1.358 (-1.883; -0.834) [2]
n≥10	16	-0.671	-1.02	-0.32	<.001	83.953	-0.809 (-1.172; -0.447) [2]
n<10	6	-1.736	-2.70	-0.77	<.001	79.899	Unchanged


Note. ^aIncluding 3 studies with MDD & Dysthymia. ^bData for a second intervention group within the same study were included for these analyses. ^cMixed exercise=aerobic and resistance exercise.

Supplementary Table 8. Meta Regression of Moderators/Correlates of Effects of Exercise on Depression for Studies with Low and Moderate Risk of Bias

Moderator	Number of RCTs	β	95%CI		p- value	R ^{2 c}
Main exercise response						
Mean age exercise	16	0.013	-0.01	0.04	.272	0.00
Mean age control	16	0.015	-0.01	0.04	.206	0.00
Duration of trial (in weeks) ^a	21	0.064	0.00	0.13	.039	0.12
Weekly frequency ^a	21	-0.005	-0.18	0.17	.954	0.00
Minutes per session ^a	19	-0.004	-0.02	0.02	.707	0.00
Sample size ^b	19	0.001	-0.00	0.00	.483	0.00
MDD (+ Dysthymia) only						
Mean age exercise	10	0.021	-0.00	0.04	.078	0.39
Mean age control	10	0.022	-0.00	0.05	.052	0.46
Duration of trial (in weeks) ^a	13	0.070	0.01	0.14	.034	0.26
Weekly frequency ^a	13	0.049	-0.15	0.24	.623	0.00
Minutes per session ^a	12	-0.021	-0.05	0.00	.095	0.26
Sample size ^b	11	0.002	-0.01	0.01	.614	0.00

Note. ^adata for a second intervention group within the same study were included for these analyses. ^bAverage sample size pre-post intervention. c R2 equal to R2 analog.

Supplementary Figure 1. Funnel Plot of Standard Error by SMD



Supplementary Material

Exercise as Medicine for Depressive Symptoms?

A Systematic Review and Meta-analysis with Meta regression

Andreas Heißel, Darlene Heinen, Luisa Leonie Brokmeier, Nora Skarabis, Maria Kangas, Davy Vancampfort, Brendon Stubbs, Joseph Firth, Philip B. Ward, Simon Rosenbaum, Mats Hallgren, Felipe Schuch

- Text 1. Full search terms
- Table 1. Data of Studies Included in Systematic Review
- Table 2. List of excluded studies at full-text screening stage, with brief reasons
- **Table 3.** Risk of Bias Assessments (ROB2)
- Table 4. Summary of included studies
- **Table 5.** Characteristics of included studies
- **Table 6.** Subgroup Meta-Analysis of studies included in the quantitative analyses with low and moderate risk of bias
- Table 7. Subgroup analysis for studies with MDD diagnosis
- **Table 8.** Meta regression of moderators/correlates of effects of exercise on depression for studies with low and moderate risk of bias
- Figure 1. Funnel Plot of Standard Error by SMD

Supplementary Text 1. Full search terms

MeSH terms

((exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR physical medicine OR resistance OR lift*) AND (depression OR dysthymia) AND (randomized controlled trial OR clinical trial))

Cochrane/ Embase

(exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR "physical medicine" OR resistance OR lift*):ti,ab,kw AND (depression OR dysthymia):ti,ab,kw AND (randomized control trial" OR "randomized clinical trial):ti,ab,kw in Trials (Word variations have been searched)

PubMed

((exercis*[Title/Abstract] OR aerobic*[Title/Abstract] OR running[Title/Abstract] OR jogging[Title/Abstract] OR walk*[Title/Abstract] OR hiking[Title/Abstract] OR swim*[Title/Abstract] OR aquatic*[Title/Abstract] OR cycling[Title/Abstract] OR bicycl*[Title/Abstract] OR strength*[Title/Abstract] AND activit*[Title/Abstract] OR fitness[Title/Abstract] OR train*[Title/Abstract] OR physical medicine[Title/Abstract] OR resistance[Title/Abstract] OR lift*[Title/Abstract]) AND (depression[Title/Abstract] OR dysthymia[Title/Abstract])) AND (randomized controlled trial[Title/Abstract]) OR clinical trial[Title/Abstract])

PsychINFO

(exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR physical medicine OR resistance OR lift*) AND (depression OR dysthymia) AND (randomized controlled trial OR clinical trial)

SPORTDiscus

(exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR physical medicine OR resistance OR lift*) AND (depression OR dysthymia) AND (randomized controlled trial OR clinical trial)

Medline

((TS=(exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR physical medicine OR resistance OR lift*)) AND TS=(depression OR dysthymia)) AND TS=(randomized controlled trial OR clinical trial)

Scopus

TITLE-ABS-KEY ((exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* AND activit* OR fitness OR train* OR physical AND medicine OR resistance OR lift*) AND (depression OR dysthymia) AND (randomized AND controlled AND trial OR clinical AND trial))

Web of Science

(exercis* OR aerobic* OR running OR jogging OR walk* OR hiking OR swim* OR aquatic* OR cycling OR bicycl* OR strength* and activit* OR fitness OR train* OR physical medicine OR resistance OR lift*) AND (depression OR dysthymia) AND (randomized controlled trial OR clinical trial) (Topic)

Supplementary Table 1. Data of Studies Included in Systematic Review

Study	Sample size	ze (n)	Outcome ^a	Pre (mean	n (SD))	Post (mea	n (SD))	Intervention			Control group condition	Diagnosis
	Exercise	Control		Exercise	Control	Exercise	Control	Type of intervention	Wks	Sessions per wk/ time per session		
Abdelbasset et al, 45 2019	23	23	PHQ-9	16.12 (3.10)	15.95 (3.14)	3.65 (1.21)	8.54 (2.14)	Aerobic exercise	12	3/30-60 min ^b	Usual care (standard medical treatment)	Depressive symptoms
Blumenthal et al, ⁶⁶ 2007 (supervised exercise)	51	49	HAM-D, BDI-II	16.40 (3.70)	17.20 (4.30)	9.20 (6.10)	11.00 (7.00)	Aerobic exercise	16	3/45 min	Placebo	MDD
Blumenthal et al, ⁶⁶ 2007 (homebased exercise)	53	49	HAM-D, BDI-II	17.30 (4.60)	17.20 (4.30)	10.20 (6.70)	11.00 (7.00)	Aerobic exercise	16	3/45 min	Placebo	MDD
Brenes et al, 46 2007	14	12	HAM-D, GDS	12.70 (3.40)	9.50 (3.70)	7.80 (4.30)	10.90 (5.80)	Mixed exercise	16	3/60 min	Usual care (phone calls to discuss health status)	Depressive symptoms
Carneiro et al, ⁶⁷ 2015	9	10	BDI-II, DASS-21	45.56 (9.65)	46.10 (11.52)	34.89 (10.56)	49.40 (16.72)	Aerobic exercise	16	3/45 min	Usual care (pharmacolog ical therapy)	MDD & Dysthymia
Chau et al, ⁶⁸ 2020	42	42	HAM-D, DASS-21	25.93 (6.59)	25.62 (8.03)	12.57 (8.06)	25.58 (7.81)	Mixed exercise	12	3/60 min	Wait-list	MDD
Cheung et al, ⁴⁸ 2018	17	17	HAM-D	18.50 (3.20)	19.40 (3.60)	9.80 (5.60)	14.50 (5.30)	Aerobic exercise	12	3/40 min	Usual care (usual psychiatric care)	MDD

Danielsson et al, ⁷⁰ 2014	22	20	MADRS	24.60 (4.10)	23.40 (5.00)	-10.30° (1.60)	-4.60° (1.70)	Aerobic exercise	10	2/60 min	Usual care (standard care)	MDD
Doose et al, ⁷¹ 2015	30	16	HAM-D, BDI-II	13.97 (2.58)	14.67 (3.91)	-9.48 ^d (11.38-7.58)	-1.24 ^d (-3.85-1.37)	Aerobic exercise	8	3/60 min	Wait-list	MDD
Doyne et al, ⁴⁷ 1987 (running condition)	14	11	HAM-D, BDI, DACL	13.36 (4.43)	12.58 (4.58)	6.64 (3.61)	13.58 (5.14)	Aerobic exercise	8	4/25 min	Wait-list	Depressive symptoms
Doyne et al, ⁴⁷ 1987 (weightlifting)	15	11	HAM-D, BDI, DACL	13.80 (7.78)	12.58 (4.58)	5.13 (3.44)	13.58 (5.14)	Resistance exercise	8	4/45 min	Wait-list	Depressive symptoms
Epstein, ⁷² 1986	7	10	BDI, SDS	25.29 (6.52)	22.00 (7.16)	9.00 (10.94)	16.30 (7.44)	Aerobic exercise	8	3/30 min	Wait-list	MDD
Gao et al, ⁴⁸ 2016	26	24	SDS	0.58 (0.10)	0.59 (0.11)	0.43 (0.09)	0.57 (0.10)	Aerobic exercise	12	5/60-90 min ^b	Usual care (lived normally without intervention)	Depressive symptoms
Gary et al, ⁷³ 2010	20	17	HAM-D	15.40 (3.40)	15.20 (3.60)	8.40 (5.60)	9.30 (4.90)	Aerobic exercise	12	3/weekly increase by 5 min to 60 min ^b	Usual care (usually provided	MDD
Hallgren et al, ⁴⁹ 2015	317	312	MADRS	22.20 (6.80)	20.90 (7.50)	11.30 (7.90)	13.80 (8.90)	Mixed exercise	12	3/60 min	Usual care (treatment as usual)	Depressive symptoms
Hemat-Far et al, ⁵⁰ 2012	10	10	BDI	25.00 (5.30)	23.80 (4.70)	16.60 (6.90)	22.80 (4.90)	Aerobic exercise	8	3/40-60 min ^b	Usual care (pursue normal live)	Depressive symptoms
Huang et al, ⁵¹ 2015	19	20	GDS-15	8.63 (3.56)	7.20 (2.19)	4.63 (2.49)	5.20 (1.69)	Mixed exercise	12	3/50 min	Usual care	Depressive symptoms

La Rocque et al, ⁷⁴ 2020	20	15	HAM-D	12.00 (3.77)	13.93 (3.71)	6.75 (6.05)	16.33 (5.84)	Aerobic exercise	8	2/50-60 min ^b	Wait-list	MDD
Legrand et al, ⁵² 2014	22	22	BDI-II	21.67 (6.78)	19.25 (9.34)	12.80 (4.38)	19.67 (8.17)	Aerobic exercise	7	2/30 min	Wait-list	Depressive symptoms
Lok et al, ⁵³ 2017	40	40	BDI	17.46 (8.07)	19.89 (5.00)	11.89 (4.23)	17.71 (4.61)	Aerobic exercise	10	4/70 min	Wait-list	Depressive symptoms
Makizako et al, ⁵⁵ 2019	30	29	GDS-15	7.10 (2.50)	6.40 (2.50)	5.30 (2.50)	5.10 (3.10)	Mixed exercise	20	1/90 min	Health education	Depressive symptoms
Mather et al, ⁴⁴ 2002	43	43	HRSD	16.70 (10.83) ^e	17.40 (10.83) ^e	12.60 (7.02)	13.70 (6.02)	Mixed exercise	10	2/55-65 min ^b	Health education	Depressive symptoms
McNeil et al, ⁵⁴ 1991	10	10	BDI	16.60 (3.10)	15.20 (2.40)	11.10 (3.00)	14.70 (3.70)	Aerobic exercise	6	3/20-40 min ^b	Wait-list	Depressive symptoms
Mota-Pereira et al, ⁷⁵ 2011	19	10	HAM-D, BDI	19.32 (1.69)	13.00 (1.42)	12.48 (1.74)	13.60 (1.34)	Aerobic exercise	6	5/30-45 min ^b	Usual care (pharmacothe rapy)	MDD
Mutrie, ⁵⁶ 1986 (aerobic exercise)	9	7	BDI, POMS	22.44 (6.82)	23.00 (5.80)	9.46 (4.28)	21.42 (5.26)	Aerobic exercise	4	3/20 min	Wait-list	Depressive symptoms
Mutrie, 56 1986 (strength & stretching)	8	7	BDI, POMS	21.86 (4.21)	23.00 (5.80)	14.63 (7.63)	21.42 (5.26)	Mixed exercise	4	3/20 min	Wait-list	Depressive symptoms
Nabkasorn et al, ⁵⁷ 2006	28	31	CES-D	20.10 (0.90)	18.80 (7.00)	14.40 (4.12)	17.50 (4.23)	Aerobic exercise	8	5/50 min	Usual care (usual daily routine)	Depressive symptoms

Oertel-Knöchel et al, ⁷⁶ 2014	8	8	BDI-II	26.25 (10.21)	25.50 (11.83)	18.75 (9.50)	24.00 (13.09)	Aerobic exercise	4	3/75 min	Wait-list	MDD
Orth, ⁵⁸ 1979	3	2	DACL, MMPI	14.00 (3.60)	19.50 (7.00)	7.00 (6.50)	16.50 (2.12)	Aerobic exercise	4	5/30 min	Self- monitoring	Depressive symptoms
Pfaff et al, ⁶⁵ 2014	108	92	SIGMA	21.02 (9.4)	21.66 (8.4)	14.43 (9.8)	14.32 (9.3)	Mixed exercise	12	5/30 min + 3x resistance training	Usual care (usual medical care)	MDD
Pilu et al, ⁷⁷ 2007	10	20	HAM-D	20.50 (7.10)	19.30 (5.70)	8.10 (5.20)	16.70 (9.10)	Resistance exercise	32	2/60 min	Usual care (pharmacothe rapy)	MDD
Prakhinkit et al, ⁵⁹ 2014 (traditional walking)	15	15	TGDS-30	17.30 (1.00)	17.90 (0.70)	15.50 (0.90)	18.60 (0.60)	Aerobic exercise	12	3/20-30 min ^b	Usual care (sedentary control group)	Depressive symptoms
Prakhinkit et al, ⁵⁹ 2014 (Buddhism walking)	15	15	TGDS-30	16.08 (0.90)	17.90 (0.70)	8.60 (0.60)	18.60 (0.60)	Aerobic exercise	12	3/20-30 min ^b	Usual care (sedentary control group)	Depressive symptoms
Roy et al, ⁷⁸ 2018	23	23	HAM-D, DSSS	19.30 (4.83)	16.55 (4.14)	15.00 (4.93)	13.85 (3.16)	Aerobic exercise	1.5	7/20 min	Usual care (treatment as usual)	MDD
Schneider et al, ⁷⁹ 2016	15	14	HAM-D, BDI-II	15.70 (4.60)	17.40 (4.30)	10.60 (6.10)	5.80 (5.41)	Mixed exercise	24	Biweekly 2/20-65 min ^b	Usual care (enhanced usual care condition)	MDD
Schuch et al, 80 2015	25	25	HAM-D	26.52 (1.80)	26.96 (2.70)	7.42 (4.47)	11.12 (4.47)	Aerobic exercise	12	3/unclear	Usual care (treatment as usual)	MDD
Setaro, 60 1985	25	25	MMPI	68.92 (5.27)	68.56 (3.87)	62.00 (6.51)	69.88 (3.96)	Aerobic exercise	10	2/unclear	Usual care (no activity or treatment)	Depressive symptoms

Shahidi et al, ⁶¹ 2011	20	20	GDS-30	15.30 (5.40)	15.20 (3.90)	11.10 (6.20)	15.20 (6.10)	Aerobic exercise	N/A	Unclear/3 0 min	Unclear	Depressive symptoms
Sims et al, ⁶² 2006	14	18	GDS	12.64 (3.61)	12.22 (3.51)	12.23 (5.22)	12.00 (4.26)	Resistance exercise	10	3/unclear	Information and advice for local options of exercise	Depressive symptoms
Sims et al, ⁶³ 2009	23	22	CES-D	15.43 (7.49)	23.27 (8.86)	15.13 (8.49)	20.62 (11.79)	Resistance exercise	10	2/unclear	Wait-list	Depressive symptoms
Singh et al, ⁸¹ 1997	17	15	HAM-D, DSM-IV, BDI, GDS	12.30 (0.90)	11.40 (1.00)	5.30 (1.30)	8.90 (1.30)	Resistance exercise	10	3/50 min	Health education	MDD & Dysthymia
Singh et al, 82 2005 (high intensity)	20	20	HAM-D, GDS	18.00 (4.50)	19.70 (3.90)	8.50 (5.50)	14.40 (6.00)	Resistance exercise	8	3/65 min	Usual care (usual care from GP)	MDD & Dysthymia
Singh et al, 82 2005 (low intensity)	20	20	HAM-D, GDS	19.50 (5.30)	19.70 (3.90)	12.40 (6.30)	14.40 (6.00)	Resistance exercise	8	3/65 min	Usual care (usual care from GP)	MDD & Dysthymia
Veale et al, ⁸³ 1992	48	35	CIS, BDI	35.87 (1.07)	37.57 (1.49)	16.80 (2.06)	26.39 (2.50)	Aerobic exercise	12	3/unclear	Usual care (usual psychiatric treatment)	MDD
Vieira et al, ⁸⁴ 2007	9	9	HAM-D	30.22 (3.04)	31.11 (3.51)	24.88 (2.13)	32.66 (3.12)	Aerobic exercise	12	2/50 min	Usual care	MDD
Williams et al, ⁶⁴ 2008 (mixed exercise)	16	12	CSDD	11.05 (2.79)	14.58 (5.75)	8.37 (5.78)	11.75 (8.10)	Mixed exercise	16	5/30 min	Social conversation	Depressive symptoms
Williams et al, ⁶⁴ 2008 (supervised walking)	17	12	CSDD	12.18 (5.00)	14.58 (5.75)	9.68 (6.57)	11.75 (8.10)	Aerobic exercise	16	5/30 min	Social conversation	Depressive symptoms

Note. BDI=Beck Depression Inventory. CES=Centre for Epidemiologic Studies Depression. CIS=Clinical Interview Schedule. CSDD=Cornel Scale for Depression in Dementia. DACL=Depression Adjective Check Lists. DASS=Depression Anxiety Stress Scale. DSSS=Depression Somatic Symptom scale. GDS=Geriatric Depression Scale. HAMD=Hamilton Depression Scale. MADRS=Montgomery-Asberg Depression Rating Scale. MDD=Major Depressive Disorder. MMPI=Minnesota Multiphasic Personality Inventory. PHQ-9=Patient Health Questionnaire. POMS=Profile of Mood States. TGDS=Thai Geriatric Depression Scale. SDS=Severity of Dependence Scale. HRSD=Hamilton Rating Scale for Depression. DACL=Depression Adjective Checklist. SIGMA=screening tool for the assessment and design of human-centered work activities. Usual care=no treatment but including psychiatric, pharmaco-, and psychotherapeutic treatment if required. Mixed exercise=aerobic and resistance exercise. Studies with two exercise groups were compared to the same control group. In case of more than one outcome, mean and SD of the first named outcome are reported. Primary outcome as indicated by authors or, if not indicated, rated by a clinician were included in the main analyses. For varying minutes per session, the average was used for calculations. Values are presented as mean changes with standard errors. Values are presented as least Square Means (95%CI). Calculation of SDs from confidence intervals.

Supplementary Table 2. List of excluded studies at full-text screening stage, with brief reasons

	Author	Reason for exclusion
1.	Abdelbasset et al, 2021	Non depressed
2.	Abedi et al, 2015	Non depressed
3.	Abrahao et al, 2015	Ineligible patient population
4.	Abrantes et al, 2017	Ineligible intervention
5.	Aider et al, 2014	Ineligible patient population
6.	Akandere et al, 2011	Non depressed
7.	Almeida et al, 2022	Ineligible intervention
8.	Alves et al, 2013	Non depressed
8.	Ansai et al, 2015	Non depressed
9.	Antunes et al, 2005	Non depressed
10.	Armstrong et al, 2004	Non depressed
11.	Bang et al, 2016	Non depressed
12.	Belvederri Murri et al, 2015	Medication
13.	Bernard, Ninot, Cyprien et al, 2015	Ineligible outcome
14.	Bernard, Ninot, Bernard et al, 2015	Non depressed
15.	Blumenthal et al, 1999	Medication
16.	Blumenthal et al, 2012	Non depressed
17.	Bolier et al, 2013	Ineligible intervention
18.	Bonnet, 2005	Ineligible intervention
19.	Bosscher, 1993	Ineligible comparator
20.	Boström et al, 2015	Non depressed
21.	Brinsley et al, 2022	Non depressed
21.	Brittle et al, 2009	Non depressed
22.	Brown et al, 2009	Non depressed
23.	Buettner, 2002	Non depressed
24.	Buschert et al, 2019	Ineligible comparator
25.	Callaghan et al, 2011	Ineligible comparator
26.	Carneiro et al, 2016	Non depressed
27.	Carta et al, 2022	Non depressed
28.	Carter et al. 2022	Ineligible age
29.	Chalder et al, 2012	Ineligible intervention
		To disting the second second
28.	Chan et al. 2012	Ineligible intervention
29. 30.	Chen et al, 2017 Chu et al, 2008	Non depressed Ineligible comparator
30.	Ciccolo et al, 2008	Ineligible intervention
31.	Conradsson et al, 2010	Non depressed
32.	Courneya et al, 2007	Ineligible patient population
33.	Craft et al, 2007	Ineligible comparator
33. 34.	de la Cerda et al, 2011	Medication
35.	de Lima et al, 2016	Non depressed
35. 36.	Dalgas et al, 2010	Ineligible patient population
30. 37.	Damush et al, 1999	Non depressed
31.	Damasii Ct ai, 1777	non depressed

38.	Deschamps et al, 2015	Ineligible comparator
39.	Dorscht et al, 2019	Ineligible comparator
40.	Dunn et al, 2002	No control group
41.	Dunn et al, 2005	Ineligible comparator
42.	Ellard et al, 2014	Non depressed
43.	Euteneuer et al, 2017	Ineligible intervention
44.	Eyigor et al, 2010	Ineligible comparator
45.	Fang et al, 2013	Ineligible comparator
46.	Foley et al, 2008	Ineligible comparator
47.	Forsyth et al, 2015	Ineligible patient population
48.	Geliebter et al, 1997	Non depressed
49.	Gerber et al, 2013	Non depressed
50.	Gerber et al, 2020	Ineligible comparator
51.	Goldfield et al, 2015	Ineligible patient population
52.	Greer et al, 2015	No control group
53.	Guifeng et al, 2015	Ineligible comparator
54.	Gujral et al, 2019	Medication
55.	Häkkinen et al, 2001	Ineligible patient population
56.	Hanssen et al, 2018	Ineligible comparator
57.	Haussleiter et al, 2020	Ineligible comparator
58.	He et al, 2022	Ineligible comparator
58.	Helgadottir et al, 2018	Secondary data
59.	Herman et al, 2002	Duplicate
60.	Herring et al, 2011	Ineligible patient population
61.	Hess-Homeier, 1981	Ineligible intervention
62.	Ho et al, 2014	Ineligible comparator
63.	Hoffmann et al, 2008	Duplicate
64.	Hoffmann et al, 2010	Ineligible patient population
65.	Holmgren et al, 2010	Non depressed
66.	Huipeng et al, 2013	Ineligible comparator
67.	Imboden et al, 2019	Ineligible comparator
68.	Isaksen et al, 2016	Non depressed
69.	Jaggers et al, 2015	Non depressed
70.	Jin et al, 2019	Non depressed
71.	Jinchun et al, 2015	Ineligible comparator
72.	Kahl et al, 2015	Ineligible outcome
73.	Karahan et al, 2017	Ineligible patient population
74.	Karg et al, 2020	Ineligible comparator
75.	Kekäläinen et al, 2018	Non depressed
76.	Kerling et al, 2015	Ineligible comparator
77.	Kerr et al, 2008	Non depressed
78.	Kerse et al, 2010	Non depressed
79.	Kim et al, 2019	Non depressed
80.	Klein et al, 1985	Ineligible comparator
81.	Knapen et al, 2003	Ineligible patient population
82.	Knubben et al, 2007	Ineligible intervention
83.	Kraepelien et al, 2015	Secondary data
84.	Kratz et al, 2014	Ineligible intervention

85.	Krogh et al, 2007	Ineligible comparator
86.	Krogh et al, 2009	Ineligible comparator
87.	Krogh et al, 2012	Ineligible comparator
88.	Krogh et al, 2013	Ineligible outcome
89.	Kruisdijk et al, 2012	Ineligible patient population
	Kruisdijk et al, 2019	Ineligible patient population
91.	Kruisdijk et al, 2020	Ineligible patient population
92.	Lau et al, 2004	Ineligible patient population
93.	Le Cheminant et al, 2014	Non depressed
94.	Legrand et al, 2007	Medication
95.	Legrand et al, 2015	Medication
96.	Levinger et al, 2011	Non depressed
97.	Li et al, 2019	Ineligible intervention
98.	Lincoln et al, 2011	Ineligible patient population
99.	Lopez-Torres Hidalgo et al, 2019	No RCT
100.	Mailey et al, 2010	Ineligible patient population
101.	Majumder et al, 2015	Ineligible patient population
102.	Martins et al, 2011	Non depressed
103.	Martinsen et al, 1985	Ineligible comparator
104.	Martiny et al, 2015	Ineligible comparator
105.	Mata et al, 2012	Non depressed
106.	Matthews et al, 2011	Non depressed
107.	Mendham et al, 2021	Non depressed
108.	Meyer et al, 2022	Ineligible intervention
108.	Midtgaard et al, 2012	No control group
109.	Moraes et al, 2022	Ineligible comparator
109.	Nasstasia et al, 2019	Ineligible patient population
110.	Naumann et al, 2020	Ineligible comparator
111.	Neidig et al, 2003	Non depressed
	Neviani et al, 2017	Secondary data
113.	Ng et al, 2017	Non depressed
114.	Niederer et al, 2017	Ineligible comparator
115.	Nordbrandt et al, 2015	Non depressed
116.	Norvell et al, 1993	Non depressed
117.	Nyberg et al, 2015	Ineligible patient population
118.	Oeland et al, 2010	Ineligible patient population
119.	Ökzan et al, 2020	Non depressed
120.	Olson et al, 2017	Ineligible comparator
121.	O'Reilly et al, 1999	Non depressed
122.	Palmer et al, 1995	Non depressed
123.	Patten et al, 2017	Ineligible intervention
124.	Payne et al, 2008	Non depressed
125.	Penninx et al, 2002	Non depressed
126.	Pentecost et al, 2015	Ineligible intervention
127.	Pereira et al, 2013	Ineligible comparator
128.	Perna et al, 2010	Non depressed
129.	Peterson et al, 2014	Non depressed
130.	Philippot et al, 2022	Ineligible comparator

130. Pibernik-Okanovic et al, 2011 Ineligible patient population 131. Piette et al, 2011 Non depressed 132. Porter et al, 2012 Non depressed 133. Puterman et al, 2014 Non depressed 134. Putiri et al, 2014 Non depressed 135. Prakhinkit et al, 2015 Non depressed 136. Rantakokko et al, 2015 Non depressed 137. Razazian et al, 2016 Non depressed 138. Reuter, 1984 Ineligible intervention 139. Rueter, 1980 Ineligible comparator 140. Sadeghi et al, 2016 Medication 141. Salehi et al, 2016 Medication 142. Sarsan et al, 2006 Non depressed 143. Schmitter et al, 2020 Study protocol 144. Scholz et al, 2006 Non depressed 145. Sherwood et al, 2016 Ineligible outcome 146. Singh et al, 2001 Secondary data 147. Siqueira et al, 2011 Non depressed 148. Sparrow et al, 2011 Non depressed 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 Ineligible intervention 152. Tapps et al, 2013 Non depressed 153. Teychenne et al, 2021 Ineligible patient population 155. Toni et al, 2016 Secondary data 156. Trivedi et al, 2011 Ineligible comparator 157. Van der Kooi et al, 2007 Ineligible patient population 158. Van der Waerden et al, 2013 Non depressed 159. Vankova et al, 2014 Non depressed 160. Verrusio et al, 2014 Non depressed 161. Vieira et al, 2018 Non depressed 162. Vizza et al, 2016 Ineligible intervention 163. Wang et al, 2021 Ineligible comparator 164. Zanuso et al, 2012 Ineligible patient population 165. Zeibig et al, 2021 Ineligible intervention 166. Zeng et al, 2020 Ineligible patient population 167. Von depressed 168. Zeibig et al, 2021 Ineligible intervention 169. Vercausio et al, 2011 Ineligible intervention 160. Vercausio et al, 2014 Ineligible intervention 161. Vieira et al, 2018 Non depressed 162. Vizza et al, 2016 Ineligible patient population 161. Vieira et al, 2018 Non depressed 162. Vizza et al, 2010 Ineligible patient population 161. Vieira et al, 2010 Ineligible intervention			
132. Porter et al, 2011 133. Puterman et al, 2021 134. Putri et al, 2012 135. Prakhinkit et al, 2015 136. Rantakokko et al, 2015 137. Razazian et al, 2016 138. Reuter, 1980 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2006 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Richardson, Himle et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 154. Teychenne et al, 2021 155. Toni et al, 2014 160. Verrusio et al, 2014 160. Verrusio et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2017 164. Zanuso et al, 2017 164. Zanuso et al, 2017 165. Zeibig et al, 2012 166. Zeibig et al, 2017 166. Zeibig et al, 2021 Ineligible patient population 167. Von depressed 168. Non depressed 179. Non depressed 180. Non depressed		et al, 2011	Ineligible patient population
133. Puterman et al, 2021 134. Putiri et al, 2012 135. Prakhinkit et al, 2015 136. Rantakokko et al, 2015 137. Razazian et al, 2016 138. Reuter, 1984 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2011 148. Sparrow et al, 2011 149. Steiner, Richardson, Himle et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Tapps et al, 2013 152. Tapps et al, 2011 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2014 160. Verrusio et al, 2018 162. Vizza et al, 2018 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2012 165. Zeibig et al, 2021 165. Zeibig et al, 2021 165. Zeibig et al, 2021 Ineligible patient population Non depressed Ineligible intervention	· · · · · · · · · · · · · · · · · · ·		•
134. Putiri et al, 2012 135. Prakhinkit et al, 2014 136. Rantakokko et al, 2015 137. Razazian et al, 2016 138. Reuter, 1984 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 154. Teychenne et al, 2011 155. Toni et al, 2016 156. Trivedi et al, 2017 157. Van der Kooi et al, 2014 161. Vieira et al, 2018 162. Vieira et al, 2018 163. Wang et al, 2017 164. Zanuso et al, 2017 164. Zanuso et al, 2017 165. Zeibig et al, 2012 166. Zeibig et al, 2012 166. Zeibig et al, 2011 167. Zeibig et al, 2017 168. Van der poulation 178. Van der kooi et al, 2018 178. Van der Waerden et al, 2019 189. Van der Waerden et al, 2019 180. Varnova et al, 2014 180. Verrusio et al, 2017 180. Van der Vaerden et al, 2019 180. Van der Waerden et al, 2019 180. Verrusio et al, 2014 180. Verrusio et al, 2018 180. Van der Waerden et al, 2019 180. Van der Waerden et al, 2019 180. Verrusio et al, 2014 180. Verrusio et al, 2014 180. Verrusio et al, 2017 180. Verrusio et al, 2018 180. Van der Waerden et al, 2019 180. Verrusio et al, 2014 180. Verrusio et al, 2017 180. Verrusio et al, 2018 180. Verrusio et al, 2019 180. Verrusio et al, 2011 180. Verrusio et al, 2014 180. Verrusio et al, 2015 180. Verrusio et al, 2016 180. Verrusio et al, 2017 180. Verrusio	·		•
135. Prakhinkit et al, 2014 136. Rantakokko et al, 2015 137. Razazian et al, 2016 138. Reuter, 1980 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salchi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 154. Teychenne et al, 2021 155. Toni et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Zanuso et al, 2017 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2012 166. Zeibig et al, 2012 166. Zeibig et al, 2021 167. Zeibig et al, 2021 168. Zeibig et al, 2021	· · · · · · · · · · · · · · · · · · ·	.1	•
136. Rantakokko et al, 2015 137. Razazian et al, 2016 138. Reuter, 1984 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2016 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2011 148. Sparrow et al, 2011 149. Steiner, Richardson, Himle et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2014 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verrusio et al, 2018 161. Vieira et al, 2016 162. Vizza et al, 2016 163. Wang et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2021 166. Zeibig et al, 2012 166. Zeibig et al, 2021 166. Zeibig et al, 2021 166. Zeibig et al, 2021 166. Zeibig et al, 2012 166. Zeibig et al, 2012 166. Zeibig et al, 2012 166. Zeibig et al, 2021 166. Zeibig et al, 2021 167. Zeibig et al, 2011 168. Von depressed 169. Non depressed 160. Non depressed 160. Verboeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2017 165. Zeibig et al, 2021 166. Zeibig et al, 2021 167. Van der Waerden et al, 2017 168. Zanuso et al, 2012 169. Zeibig et al, 2021 160. Verhouse et al, 2017 160. Verhouse et al, 2017 160. Verhouse et al, 2018 161. Vieira et al, 2016 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2017 165. Zeibig et al, 2021 165. Zeibig et al, 2021	134. Putiri et al, 2012		Ineligible patient population
137. Razazian et al, 2016 138. Reuter, 1984 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2011 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2011 155. Toni et al, 2011 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verrusio et al, 2018 161. Vieira et al, 2018 162. Zapetidou et al, 2017 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 166. Zeibig et al, 2012 166. Zeibig et al, 2012 166. Zeibig et al, 2011 167. Von depressed 168. Vancou et al, 2017 169. Vancou et al, 2018 160. Vernoeven et al, 2019 160. Vernoeven et al, 2019 160. Vernoeven et al, 2019 161. Vieira et al, 2016 162. Vizza et al, 2016 163. Zanuso et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2021 166. Jeneigible intervention 167. Von depressed 168. Vancou et al, 2017 169. Zeibig et al, 2021 160. Vernoeven et al, 2017 160. Vernoeven et al, 2018 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2017 165. Zeibig et al, 2021 166. Zeibig et al, 2021 167. Van depressed 168. Vizza et al, 2016 169. Vernoeven et al, 2017 160. Vernoeven et al, 2019 161. Vieira et al, 2016 162. Vizza et al, 2016 163. Vancoe et al, 2017 164. Zanuso et al, 2011 165. Zeibig et al, 2021	135. Prakhinkit et al, 20	14	No control group
138. Reuter, 1984 139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salchi et al, 2016 142. Sarsan et al, 2020 143. Schmitter et al, 2020 144. Scholz et al, 2016 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 154. Teychenne et al, 2016 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2012 164. Zanuso et al, 2012 165. Zeibig et al, 2021 Ineligible patient population Secondary data Non depressed	-		-
139. Rueter, 1980 140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2016 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2014 160. Verhoeven et al, 2018 162. Vizza et al, 2018 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2012 Ineligible patient population Secondary data Non depressed Non depressed Non depressed Non depressed Ineligible patient population Non depressed Non depressed Ineligible comparator Ineligible patient population Non depressed Non depressed Ineligible patient population Non depressed Non depressed Non depressed Ineligible patient population Non depressed Non depressed Non depressed Ineligible patient population Non depressed	137. Razazian et al, 2010	6	Non depressed
140. Sadeghi et al, 2016 141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2011 147. Siqueira et al, 2011 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verrousio et al, 2018 161. Vieira et al, 2018 162. Vizza et al, 2012 163. Zanetidou et al, 2012 165. Zeibig et al, 2012 166. Zeibig et al, 2021 Ineligible patient population 167. Van der Kooi et al, 2014 Ineligible intervention Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible patient population	138. Reuter, 1984		Ineligible intervention
141. Salehi et al, 2016 142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2019 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2014 158. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2012 165. Zeibig et al, 2012 166. Zeibig et al, 2021 Ineligible patient population Secondary data Ineligible comparator Ineligible intervention Non depressed Ineligible intervention Secondary data Ineligible patient population Non depressed Ineligible intervention Non depressed Ineligible intervention Non depressed	139. Rueter, 1980		Ineligible comparator
142. Sarsan et al, 2006 143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2011 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2012 Ineligible intervention Non depressed Non depressed Non depressed Non depressed Non depressed Non depressed Ineligible patient population Non depressed Ineligible intervention Non depressed Ineligible patient population Non depressed Ineligible patient population Non depressed Ineligible patient population Non depressed	140. Sadeghi et al, 2016		
143. Schmitter et al, 2020 144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2018 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2012 166. Ineligible patient population 166. Zanetidou et al, 2017 167. Secondary data 168. Non depressed 169. Vizza et al, 2014 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 166. Ineligible patient population 167. Secondary data 168. Non depressed 169. Vizza et al, 2016 169. Vizza et al, 2016 160. Vieira et al, 2017 160. Zenetidou et al, 2017 161. Vieira et al, 2012 162. Vizza et al, 2016 163. Vang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 165. Ineligible patient population 166. Verrusio et al, 2017 167. Secondary data 168. Non depressed 169. Vizza et al, 2016 169. Vizza et al, 2019 169. Vizza et al, 2019 160. Vizia et al, 2019 160. Vieira et al, 2019 161. Vieira et al, 2019 162. Vizza et al, 2019 163. Zanetidou et al, 2019 164. Zanuso et al, 2021	141. Salehi et al, 2016		Medication
144. Scholz et al, 2006 145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2013 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2012 166. Teiligible patient population 167. Van der Kooi et al, 2014 168. Vizza et al, 2016 169. Vizza et al, 2016 160. Verrusio et al, 2017 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 165. Zeibig et al, 2021 166. Ineligible patient population 167. Van depressed 168. Vizza et al, 2016 169. Verrusio et al, 2017 160. Verrusio et al, 2017 160. Verrusio et al, 2019 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 165. Ineligible patient population 167. Vieira et al, 2018 168. Vizza et al, 2019 169. Vizza et al, 2019 160. Verrusio et al, 2019 161. Vieira et al, 2019 162. Vizza et al, 2016 163. Vang et al, 2021 164. Zanuso et al, 2011 165. Zeibig et al, 2021	142. Sarsan et al, 2006		Non depressed
145. Sherwood et al, 2016 146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Vernusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2021 168. Ineligible outcome Secondary data 169. Ineligible intervention 180. Ineligible intervention 181. Vieira et al, 2014 182. Vizza et al, 2016 183. Vizza et al, 2016 184. Zanuso et al, 2017 185. Secondary data 186. Vizza et al, 2016 186. Vizza et al, 2016 187. Vizza et al, 2016 188. Non depressed 189. Vizza et al, 2016 189. Vizza et al, 2017 189. Vizza et al, 2016 199. Vizza et al, 2016 199. Vizz	143. Schmitter et al, 202	20	Study protocol
146. Singh et al, 2001 147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2012 165. Zeibig et al, 2021 166. Secondary data 167. Ineligible patient population 168. Non depressed 169. Vizza et al, 2016 Ineligible intervention Non depressed Ineligible intervention Non depressed Ineligible intervention Non depressed Ineligible patient population Non depressed Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible patient population Ineligible intervention Ineligible patient population	144. Scholz et al, 2006		Non depressed
147. Siqueira et al, 2016 148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2012 166. Zeibig et al, 2012 167. Van der Kooi et al, 2018 168. Vizza et al, 2018 169. Vizza et al, 2019 160. Vernusio et al, 2019 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 166. Trivedi et al, 2012 167. Vander Wander	145. Sherwood et al, 201	16	Ineligible outcome
148. Sparrow et al, 2011 149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2012 166. Teivedi et al, 2017 167. Van der Waerden et al, 2018 168. Vander Waerden et al, 2019 169. Verrusio et al, 2014 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible intervention Secondary data Non depressed Ineligible patient population	146. Singh et al, 2001		Secondary data
149. Steiner, Bigatti, Ang et al, 2015 150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2012 166. Zeibig et al, 2012 167. Van der Waerden et al, 2018 168. Van der Waerden et al, 2019 169. Verrusio et al, 2018 160. Verrusio et al, 2018 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2021 164. Zanuso et al, 2012 165. Zeibig et al, 2021 166. Veressed 167. Vieira et al, 2019 170. Vieira et al, 2019 180. Vizza et al, 2016 180. Vizza et al, 201	147. Siqueira et al, 2016		Medication
150. Steiner, Richardson, Himle et al, 2015 151. Ström et al, 2013 152. Tapps et al, 2013 153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al, 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Ineligible intervention Ineligible intervention Non depressed Ineligible comparator Ineligible intervention Non depressed Ineligible intervention Non depressed Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Non depressed Ineligible patient population	148. Sparrow et al, 2011		Non depressed
Ineligible intervention 152. Tapps et al, 2013 Non depressed 153. Teychenne et al, 2019 Non depressed 154. Teychenne et al, 2021 Ineligible patient population 155. Toni et al, 2016 Secondary data 156. Trivedi et al, 2011 Ineligible comparator 157. Van der Kooi et al, 2007 Ineligible patient population 158. Van der Waerden et al, 2013 Non depressed 159. Vankova et al, 2014 Non depressed 160. Verhoeven et al. 2022 Ineligible comparator Ineligible comparator Ineligible intervention Non depressed Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible intervention Ineligible intervention Ineligible intervention Ineligible patient population	149. Steiner, Bigatti, An	g et al, 2015	Non depressed
152. Tapps et al, 2013 Non depressed 153. Teychenne et al, 2021 Ineligible patient population 155. Toni et al, 2016 Secondary data 156. Trivedi et al, 2011 Ineligible comparator 157. Van der Kooi et al, 2007 Ineligible patient population Non depressed 158. Van der Waerden et al, 2013 Non depressed 159. Vankova et al, 2014 Non depressed 160. Verhoeven et al. 2022 Ineligible comparator Ineligible comparator Ineligible comparator Ineligible patient population Non depressed Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible intervention Non depressed Ineligible intervention Secondary data Ineligible intervention Non depressed Ineligible intervention Secondary data Non depressed Ineligible patient population Ineligible intervention Ineligible intervention Ineligible intervention Ineligible patient population	150. Steiner, Richardson	n, Himle et al, 2015	Ineligible intervention
153. Teychenne et al, 2019 154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al. 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2012 165. Zeibig et al, 2021 Non depressed Non depressed Ineligible comparator Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible patient population Ineligible intervention Ineligible intervention Ineligible patient population Ineligible patient population Ineligible patient population	151. Ström et al, 2013		Ineligible intervention
154. Teychenne et al, 2021 155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al. 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Ineligible patient population Ineligible comparator Ineligible intervention Non depressed Ineligible patient population Ineligible patient population Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible patient population Ineligible patient population Ineligible intervention	152. Tapps et al, 2013		Non depressed
155. Toni et al, 2016 156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al. 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Ineligible comparator Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible intervention Ineligible patient population Ineligible intervention Ineligible patient population Ineligible patient population Ineligible patient population	153. Teychenne et al, 20	19	Non depressed
156. Trivedi et al, 2011 157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al. 2022 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Ineligible comparator Ineligible comparator Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible intervention Ineligible intervention Ineligible patient population Ineligible intervention Ineligible patient population	154. Teychenne et al, 20	21	Ineligible patient population
157. Van der Kooi et al, 2007 158. Van der Waerden et al, 2013 159. Vankova et al, 2014 160. Verhoeven et al. 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Ineligible patient population Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible intervention Ineligible patient population Ineligible patient population	155. Toni et al, 2016		Secondary data
158. Van der Waerden et al, 2013 Non depressed 159. Vankova et al, 2014 Non depressed 160. Verhoeven et al. 2022 Ineligible comparator 160. Verrusio et al, 2014 Ineligible intervention Non depressed 161. Vieira et al, 2018 Non depressed 162. Vizza et al, 2016 Ineligible patient population 163. Wang et al, 2022 Ineligible intervention 164. Zanuso et al, 2017 Secondary data Non depressed 165. Zeibig et al, 2021 Ineligible patient population	156. Trivedi et al, 2011		Ineligible comparator
159. Vankova et al, 2014 160. Verhoeven et al. 2022 160. Verrusio et al, 2014 161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 164. Zanuso et al, 2017 165. Zeibig et al, 2021 Non depressed Ineligible intervention Non depressed Ineligible patient population Ineligible intervention Secondary data Non depressed Ineligible patient population	157. Van der Kooi et al,	2007	Ineligible patient population
160.Verhoeven et al. 2022Ineligible comparator160.Verrusio et al, 2014Ineligible intervention161.Vieira et al, 2018Non depressed162.Vizza et al, 2016Ineligible patient population163.Wang et al, 2022Ineligible intervention163.Zanetidou et al, 2017Secondary data164.Zanuso et al, 2012Non depressed165.Zeibig et al, 2021Ineligible patient population	158. Van der Waerden e	t al, 2013	
160. Verrusio et al, 2014Ineligible intervention161. Vieira et al, 2018Non depressed162. Vizza et al, 2016Ineligible patient population163. Wang et al, 2022Ineligible intervention163. Zanetidou et al, 2017Secondary data164. Zanuso et al, 2012Non depressed165. Zeibig et al, 2021Ineligible patient population	159. Vankova et al, 2014	4	•
161. Vieira et al, 2018 162. Vizza et al, 2016 163. Wang et al, 2022 163. Zanetidou et al, 2017 164. Zanuso et al, 2012 165. Zeibig et al, 2021 Non depressed Non depressed Non depressed Non depressed Ineligible patient population	160. Verhoeven et al. 20	22	-
 162. Vizza et al, 2016 Ineligible patient population 163. Wang et al, 2022 Ineligible intervention 163. Zanetidou et al, 2017 Secondary data 164. Zanuso et al, 2012 Non depressed 165. Zeibig et al, 2021 Ineligible patient population 	•	1	
 163. Wang et al, 2022 Ineligible intervention 163. Zanetidou et al, 2017 Secondary data 164. Zanuso et al, 2012 Non depressed 165. Zeibig et al, 2021 Ineligible patient population 			
 163. Zanetidou et al, 2017 Secondary data 164. Zanuso et al, 2012 Non depressed 165. Zeibig et al, 2021 Ineligible patient population 	-		
 164. Zanuso et al, 2012 165. Zeibig et al, 2021 Non depressed Ineligible patient population 			_
165. Zeibig et al, 2021 Ineligible patient population		17	
	·		-
166. Zeng et al, 2020 Ineligible intervention	_		
	166. Zeng et al, 2020		Ineligible intervention

Note. Of the k=218 papers reviewed in full-text, k=177 were excluded.

Study	Intervention group	Comparator	D1	D2	D3	D4	D5	Overall
Abdelbasset et al, ⁴² 2019	Aerobic exercise	Usual care	!	+	+	+	+	!
Blumenthal et al, ⁶³ 2007	Aerobic exercise	Placebo	+	•	+	+	+	+
Brenes et al, 43 2007	Mixed exercise	Usual care	!	+	+		!	-
Carneiro et al, ⁶⁴ 2015	Usual care*aerobic exercise	Usual care	•	1	+		!	-
Chau et al, ⁶⁵ 2020	Mixed exercise	Wait-list	•	+	+	+	+	+
Cheung et al, 48 2018	Aerobic exercise	Usual care	•	+	+	+	+	+
Danielsson et al, ⁶⁷ 2014	Usual care*aerobic exercise	Usual care	•	+	+	+	+	+
Doose et al, ⁶⁸ 2015	Aerobic exercise	Wait-list	!	+	+		+	-
Doyne et al, 44 1987	Mixed exercise	Wait-list	+	+		+	•	
Epstein, ⁶⁹ 1986	Aerobic exercise	Wait-list	!		!	!	!	-
Gao et al, ⁴⁵ 2016	Aerobic exercise	Usual care	•	1	+	!	+	!
Gary et al, 70 2010	Aerobic exercise	Usual care	!	1	+	+	+	!
Hallgren et al, 46 2015	Mixed exercise	Usual care	•	+	+	+	+	+
Hemat-Far et al, ⁴⁷ 2012	Aerobic exercise	Usual care	-	1	+		+	-

Huang et al, 48 2015	Mixed exercise	Usual care	• •	+	!	+	!
La Rocque et al, ⁷¹ 2020	Aerobic exercise	Wait-list	+ +	+	+	+	+
Legrand et al, ⁴⁹ 2014	Aerobic exercise	Wait-list	+ +	+		!	-
Lok et al, ⁵⁰ 2017	Aerobic exercise	Wait-list	! +	+	-	-	-
Makizako et al, ⁵² 2019	Mixed exercise	Health education	• •	•	!	+	!
Mather et al,41 2002	Mixed exercise	Health education	! 4	+	!	+	!
McNeil et al, ⁵¹ 1991	Aerobic exercise	Wait-list	1 4	+	-	!	-
Mota-Pereira et al, ⁷² 2011	Usual care*aerobic exercise	Usual care	!	!	+	+	-
Mutrie, ⁵³ 1986	Mixed exercise	Wait-list	• •	+		-	-
Mutrie, ⁵³ 1986 Nabkasorn et al, ⁵⁴ 2006	Mixed exercise Aerobic exercise	Wait-list Usual care	• • • • • • • • • • • • • • • • • • •	1		1	-
			• • • • • • • • • • • • • • • • • • •	•		!	- - !
Nabkasorn et al, ⁵⁴ 2006 Oertel-Knöchel et al, ⁷³	Aerobic exercise	Usual care	+		1	!	!
Nabkasorn et al, ⁵⁴ 2006 Oertel-Knöchel et al, ⁷³ 2014	Aerobic exercise Aerobic exercise	Usual care Wait-list		•	1 +		!
Nabkasorn et al, ⁵⁴ 2006 Oertel-Knöchel et al, ⁷³ 2014 Orth, ⁵⁵ 1979	Aerobic exercise Aerobic exercise Aerobic exercise	Usual care Wait-list Self-monitoring	•	•		•	
Nabkasorn et al, ⁵⁴ 2006 Oertel-Knöchel et al, ⁷³ 2014 Orth, ⁵⁵ 1979 Pfaff et al, ⁶² 2014	Aerobic exercise Aerobic exercise Aerobic exercise Mixed exercise	Usual care Wait-list Self-monitoring Usual care	• •	•		•	

Schneider et al, ⁷⁶ 2016	Mixed exercise	Usual care + + + +	+ +
Schuch et al, ⁷⁷ 2015	Aerobic exercise	Usual care + + + +	+ +
Setaro, ⁵⁷ 1985	Aerobic exercise	Usual care + + + +	+ +
Shahidi et al, ⁵⁸ 2011	Aerobic exercise	Unclear !	!
Sims et al, ⁵⁹ 2006	Resistance exercise	Advise for activity + + !	<u> </u>
Sims et al, ⁶⁰ 2009	Resistance exercise	Wait-list + + !	<u> </u>
Singh et al, 78 1997	Resistance exercise	Health education	!
Singh et al, ⁷⁹ 2005	Resistance exercise	Usual care + + + +	+ +
Veale et al, 80 1992	Aerobic exercise	Usual care - !	!
Vieira et al,81 2007	Aerobic exercise	Usual care ! + +	!
Williams et al, ⁶¹ 2008	Mixed exercise	Social conversation + + + +	

Note. += low risk, != some concerns, -= high risk, D1 = Randomisation process, D2 = Deviations from the intended interventions, D3 = Missing outcome data, D4 = Measurement of the outcome, D5 = Selection of the reported result.

Author, year, country	Age (mean	or range)	Gender (%	(females)	Antidepress (% taking)	sant use	Thesis or Peer- reviewed article
	Exercise	Control	Exercise	Control	Exercise	Control	
Abdelbasset et al, ⁴² 2019, Saudi-Arabia Blumenthal et al, ⁶³	52.60	52.90	31.00	26.00	N/A	N/A	Peer-reviewed
2007, USA	52.00	52.00	75.00	77.00	0	0	Peer-reviewed
Brenes et al, ⁴³ 2007, USA	73.50	73.90	64.00	50.00	0	0	Peer-reviewed
Carneiro et al, ⁶⁴ 2015, Portugal	52.78	47.80	100	100	100	100	Peer-reviewed
Chau et al, ⁶⁵ 2020, Hong Kong	N/A	N/A	74.00	86.00	83.00	83.00	Peer-reviewed
Cheung et al, 48 2018, Hong Kong/ China	47.40	48.10	88.20	70.60	94.12	88.24	Peer-reviewed
Danielsson et al, ⁶⁷ 2014, Sweden	44.70	46.30	73.00	80.00	100	100	Peer-reviewed
Doose et al, ⁶⁸ 2015, Germany	46.10	51.25	60.00	68.80	50.00	75.00	Peer-reviewed
Doyne et al, ⁴⁴ 1987, USA	28.58	29.46	100	100	0	0	Peer-reviewed
Epstein, ⁶⁹ 1986, USA	24-60	24-60	N/A	N/A	N/A	N/A	Thesis
Gao et al, ⁴⁵ 2016, China	54.50	53.50	100	100	0	0	Peer-reviewed
Gary et al, ⁷⁰ 2010, USA	30-70	30-70	N/A	N/A	N/A	N/A	Peer-reviewed

Hallgren et al, 46 2015,	18-71	18-71	N/A	N/A	31.00	24.00	Peer-reviewed
Sweden	10 /1	10 /1	1,771	1,771	21.00	200	100110110110
Hemat-Far et al, ⁴⁷ 2012, Iran	18-25	18-25	100	100	N/A	N/A	Peer-reviewed
Huang et al, ⁴⁸ 2015, Taiwan	76.42	75.85	57.90	55.00	0	0	Peer-reviewed
La Rocque et al, ⁷¹ 2020, Canada	34.85	29.40	100	100	20.00	46.70	Peer-reviewed
Legrand et al, ⁴⁹ 2014, France	19 - 30	19-30	100	100	0	0	Peer-reviewed
Lok et al, ⁵⁰ 2017, Turkey	≥65.00	≥65.00	42.50	47.50	0	0	Peer-reviewed
Makizako et al, ⁵² 2019, Japan	73.10	73.00	53.30	51.70	0	0	Peer-reviewed
Mather et al, ⁴¹ 2002, United Kingdom	63.70	66.20	84.00	53.00	100	100	Peer-reviewed
McNeil et al, ⁵¹ 1991, Canada	N/A	N/A	N/A	N/A	0	0	Peer-reviewed
Mota-Pereira et al, ⁷² 2011, Portugal	48.68	45.33	57.90	80.00	100	100	Peer-reviewed
Mutrie, ⁵³ 1986, United Kingdom	45.70	41.10	N/A	N/A	0	0	Thesis
Nabkasorn et al, ⁵⁴ 2006, Thailand	18.70	18.80	100	100	0	0	Peer-reviewed
Oertel-Knöchel et al, ⁷³ 2014, Germany	36.60	42.20	50.00	37.50	100	100	Peer-reviewed
Orth, ⁵⁵ 1979, USA	N/A	N/A	N/A	N/A	N/A	N/A	Thesis
Pfaff et al, ⁶² 2014, Australia	61.20	60.70	62.00	64.10	60.20	47.80	Peer-reviewed

Pilu et al, 74 2007, Italy	40-60	40-60	100	100	100	100	Peer-reviewed
Prakhinkit et al, ⁵⁶ 2014, Thailand	74.80	81.00	100	100	0	0	Peer-reviewed
Roy et al, ⁷⁵ 2018, India	31.10	32.90	100	100	N/A	N/A	Peer-reviewed
Schneider et al, ⁷⁶ 2016, USA	53.30	53.60	100	100	N/A	N/A	Peer-reviewed
Schuch et al, ⁷⁷ 2015, Brazil	38.84	41.76	72.00	76.00	84.00	96.00	Peer-reviewed
Setaro, ⁵⁷ 1985, USA	N/A	N/A	N/A	N/A	N/A	N/A	Thesis
Shahidi et al, ⁵⁸ 2011, Iran	65.70	68.40	100	100	N/A	N/A	Peer-reviewed
Sims et al, ⁵⁹ 2006, Australia	75.25	74.30	85.71	50.00	0	0	Peer-reviewed
Sims et al, ⁶⁰ 2009, Australia	67.95	66.27	39.00	41.00	0	0	Peer-reviewed
Singh et al, ⁷⁸ 1997, USA	70.00	72.00	70.60	53.30	0	0	Peer-reviewed
Singh et al, ⁷⁹ 2005, Australia	69.00	69.00	55.00	50.00	0	0	Peer-reviewed
Veale et al, ⁸⁰ 1992, United Kingdom	19-58	19-58	N/A	N/A	45.00	34.00	Peer-reviewed
Vieira et al, ⁸¹ 2007, Brazil	N/A	N/A	100	100	100	100	Peer-reviewed
Williams et al, 61 2008, USA	/1-101	71-101	N/A	N/A	36.00	36.00	Peer-reviewed

Note. Not available (N/A).

Supplementary Table 5. Characteristics of Included Studies

Study	Comorbidities	Group exercise	Setting	Intensity	Supervised	Type of supervision
Abdelbasset et al, ⁴² 2019	Yes	Unclear	Outpatient	Moderate	Supervised	Unclear
Blumenthal et al, ⁶³ 2007 (supervised exercise)	No	Yes	Outpatient	Vigorous	Supervised	Unclear
Blumenthal et al, ⁶³ 2007 (homebased exercise)	No	No	Outpatient	Vigorous	Unsupervised	None
Brenes et al, 43 2007	No	Yes	Outpatient	Unclear	Supervised	Exercise professional (certified ACSM exercise leader)
Carneiro et al, ⁶⁴ 2015	No	Yes	Outpatient	Moderate	Supervised	Exercise professional (physical training teacher)
Chau et al, ⁶⁵ 2020	No	Yes	Inpatient	Moderate	Supervised	Exercise professional (physiotherapist)
Cheung et al, ⁴⁸ 2018	No	No	Outpatient	Moderate	Supervised	Exercise professional (qualified personal trainer)
Danielsson et al, ⁶⁷ 2014	No	No	Outpatient	Vigorous	Supervised	Exercise professional (physiotherapist)
Doose et al, ⁶⁸ 2015	No	Yes	Outpatient	Light	Supervised	Other (teams of coaches and medical students)
Doyne et al, 44 1987	No	No	Outpatient	Vigorous	Supervised	Other (trained undergraduate exercise

(running condition)						monitors)
Doyne et al, ⁴⁴ 1987 (weightlifting)	No	No	Outpatient	Moderate	Supervised	Other (trained undergraduate exercise monitors)
Epstein, ⁶⁹ 1986	No	Yes	Outpatient	Moderate	Supervised	Other (clinical graduate students)
Gao et al, 45 2016	No	Yes	Outpatient	Moderate	Supervised	Exercise professional (professional coach and doctor)
Gary et al, ⁷⁰ 2010	Yes	No	Outpatient	Moderate	Unsupervised	None
Hallgren et al, ⁴⁶ 2015	No	Yes	Outpatient	Light to vigorous ^b	Supervised	N/A
Hemat-Far et al, ⁴⁷ 2012	No	Unclear	Outpatient	Moderate	Supervised	Other (researcher)
Huang et al, ⁴⁸ 2015	No	Yes	Outpatient	Moderate	Supervised	Exercise professional (trained physical fitness instructor)
La Rocque et al, ⁷¹ 2020	Yes	Yes	Outpatient	Moderate	Supervised	Exercise professional (professional exercise instructor)
Legrand et al, 49 2014	No	Yes	Outpatient	Moderate	Supervised	Exercise professional (certified zumba instructor)
Lok et al, ⁵⁰ 2017	Unclear	Yes	Outpatient	Moderate	Supervised	Other (researcher)
Makizako et al, ⁵² 2019	Yes	Yes	Outpatient	Moderate	Supervised	Exercise professional (trained instructors)
Mather et al,41 2002	No	Yes	Outpatient	Unclear	Supervised	Other (instructor)
McNeil et al, ⁵¹ 1991	No	No	Outpatient	Vigorous	66% supervised & 33% unsupervised ^c	Other (undergraduate psychology student)

Mota-Pereira et al, ⁷² 2011	No	No	Outpatient	Moderate	20% supervised & 80% unsupervised ^c	Exercise professional
Mutrie, ⁵³ 1986 (aerobic exercise)	No	Unclear	Outpatient	Moderate	Unsupervised	None
Mutrie, ⁵³ 1986 (strength & stretching)	No	Unclear	Outpatient	Vigorous	Unsupervised	None
Nabkasorn et al, ⁵⁴ 2006	No	Yes	Outpatient	Moderate	Supervised	Exercise professional (physical fitness instructor)
Oertel-Knöchel et al, ⁷³ 2014	No	Yes	Inpatient	Moderate	Supervised	Exercise professional (trained physical fitness instructor
Orth, ⁵⁵ 1979	No	Unclear	Outpatient	Moderate	Unsupervised	None
Pfaff et al, ⁶² 2014	No	No	Outpatient	Moderate to vigorous	Unsupervised	None
Pilu et al, ⁷⁴ 2007	No	Yes	Outpatient	Unclear	Supervised	Exercise professional (skilled instructor with isef (physical education) diploma, psychology degree and post-degree diploma in sport psychopathology (MS)
Prakhinkit et al, ⁵⁶ 2014 (traditional walking)	No	Unclear	Outpatient	Moderate	Supervised	Other (researcher)
Prakhinkit et al, ⁵⁶ 2014 (Buddhism walking)	No	Unclear	Outpatient	Moderate	Supervised	Other (researcher)
Roy et al, ⁷⁵ 2018	Unclear	Yes	Inpatient	Moderate	Supervised	Other (registered nurse)
Schneider et al, ⁷⁶ 2016	Yes	Yes ^a	Outpatient	Moderate	Supervised	Exercise professional (pilates/yoga

						instructor)
Schuch et al, ⁷⁷ 2015	No	No	Inpatients	Unclear	Supervised	Exercise professional (researcher and sport-scientist)
Setaro, ⁵⁷ 1985	No	Yes	Outpatient	Unclear	Supervised	Exercise professional (certified aerobic dance instructor)
Shahidi et al, ⁵⁸ 2011	No	Yes	Outpatient	Unclear	Unclear	Unclear
Sims et al, ⁵⁹ 2006	No	No	Outpatient	Vigorous	Supervised	Unclear
Sims et al, 60 2009	Yes	Yes	Outpatient	Vigorous	Supervised	Exercise professional (accredited fitness trainer)
Singh et al, 78 1997	No	Yes	Outpatient	Vigorous	Supervised	Other (researcher/principal investigator)
Singh et al, ⁷⁹ 2005 (high intensity)	No	Yes	Outpatient	Vigorous	Supervised	Unclear
Singh et al, ⁷⁹ 2005 (low intensity)	No	Yes	Outpatient	Light	Supervised	Unclear
Veale et al,80 1992	No	Yes	Outpatient	Unclear	Supervised	Unclear
Vieira et al,81 2007	No	Yes	Inpatient	Moderate	Supervised	Unclear
Williams et al, 61 2008 (mixed exercise)	Yes	No	Outpatient	Unclear	Supervised	Other (graduate nursing or physical therapy students)
Williams et al, ⁶¹ 2008 (supervised walking)	Yes	No	Outpatients	Unclear	Supervised	Other (graduate nursing or physical therapy students)
Vieira et al, 81 2007 Williams et al, 61 2008 (mixed exercise) Williams et al, 61 2008	No Yes Yes	Yes No	Inpatient Outpatient Outpatients	Moderate Unclear	Supervised Supervised	Unclear Other (graduate nursing or physical therapy students) Other (graduate nursing or physical

Note. Not available (N/A). American College of Sports Medicine (ACSM). ^aParticipants were asked to additionally train once a week at home. ^bParticipants were randomized to light, moderate, and vigorous intensity exercise. In the subgroup analysis, this study was rated as moderate. ^cStudy was rated as supervised in the subgroup analyses.

		Meta an	J 515			Heterogeneity	Trim and fill effect size	
	of RCTs						(95%CI) [adjusted studies]	
		SMD	95	5%CI	p- value	ie I ²		
Main analysis	19	-0.717	-1.01	-0.43	<.001	82.372	-0.897 (-1.219; -0.575) [3]	
Depression								
classification								
MDD^{a}	11	-0.567	-0.94	-0.20	.003	78.114	Unchanged	
Depressive symptoms	8	-0.951	-1.47	-0.43	<.001	87.373	-1.115 (-1.707; -0.523) [1]	
Type of control condition	1							
Usual care	12	-0.763	-1.13	-0.40	<.001	83.728	-0.973 (-1.403; -0.543) [2]	
Wait list	3	-1.315	-1.89	-0.74	<.001	46.548	-1.678 (-2.252; -1.105) [2]	
Health education	2	-0.107	-0.44	0.23	.528	0.000	N/A	
Intensity of exercise ^b								
Light	1	-0.293	-0.95	0.37	.383	0.000	N/A	
Moderate	13	-0.775	-1.17	-0.38	<.001	85.562	-0.977 (-1.422; -0.532) [2]	
Vigorous	4	-0.324	-0.61	-0.04	.028	28.767	-0.254 (-0.550; 0.043) [1, right of mean]	
Exercise type ^b							•	
Aerobic	12	-0.891	-1.32	-0.46	<.001	81.277	-1.254 (-1.760; -0.747) [4]	
Resistance	2	-0.508	-0.98	-0.04	.033	0.000	N/A	
Mixed ^c	7	-0.396	-0.79	-0.00	.049	84.939	Unchanged	
Group exercise ^b							-	
Yes	13	-0.646	-0.97	-0.38	<.001	80.129	Unchanged	
No	6	-0.330	-0.58	-0.08	.010	33.470	-0.205 (-0.474; 0.063) [2, right of mean]	
Supervision ^b								

Yes ^d	17	-0.769	-1.08	-0.46	<.001	82.500	-0.906 (-1.236; -0.576) [2]
No	4	-0.119	-0.34	0.10	.293	0.000	-0.098 (-0.308; 0.111) [2, right
_							of mean]
Type of supervision ^b							
Exercise professional	11	-0.830	-1.22	-0.45	<.001	74.192	Unchanged
Other professional/	1	-0.061	-0.49	0.36	.778	0.000	N/A
student							
Sample size							
intervention arm ^b							
n≥25	9	-0.516	-0.84	-0.19	.002	84.053	-0.576 (-0.890; -0.261) [1]
n<25	12	-0.801	-1.25	-0.35	<.001	76.648	-1.148 (-1.612; -0.683) [4]
n≥10	19	-0.665	-0.94	-0.39	<.001	83.059	Unchanged
n<10	2	-0.588	-1.52	0.34	.215	0.000	N/A

Note. See Supplement eTable 2, 3 and 4 for detailed categorization for each study. MDD=Major depressive Disorder; RCT=Randomized Controlled Trial, SMD=Standard mean difference. aIncluding 3 studies with MDD & Dysthymia 6,77,78 bData for a second intervention group within the same study were included for these analyses. Mixed exercise=aerobic and resistance exercise. Two studies were partly supervised, see Supplement Table 5.

Supplementary Table 7. Subgroup Analysis for Studies with MDD Diagnosis^a

Analysis	Numbe r of	Meta analysis				Heterogeneity	Trim and fill effect size (95% CI)	
	RCTs						[adjusted studies]	
	11015	SMD	95	% CI	p- value	I^2	[adjasted stadies]	
Main analysis MDD	20	-0.998	-1.39	-0.61	<.001	85.746	-1.167 (-1.591; -0.742) [2]	
Risk of bias								
Low risk of bias	9	-0.607	-1.03	-0.18	.005	82.240	-0.462 (-0.921; -0.003) [1,	
							right of mean]	
Some concerns	2	-0.300	-0.87	0.27	.302	0.000	N/A	
High risk of bias	9	-1.687	-2.53	-0.84	<.001	89.056	Unchanged	
Type of control condition	on							
Usual care	13	-0.762	-1.19	-0.34	<.001	81.767	-0.999 (-1.480; -0.518) [2]	
Wait list	5	-1.443	-1.82	-1.07	<.001	18.443	-1.606 (-2.017; -1.195) [2]	
Health education	1	-3.462	-4.56	-2.37	<.001	0.000	N/A	
Intensity of exercise ^b								
Light	2	-1.041	-2.53	0.45	.170	88.867	N/A	
Moderate	12	-1.012	-1.57	-0.45	<.001	86.889	-1.317 (-1.987; -0.639) [2]	
Vigorous	5	-0.881	-1.62	-0.15	.019	88.544	-1.152 (-2.039; -0.265) [1]	
Exercise type ^b								
Aerobic	15	-0.893	-1.29	-0.50	<.001	80.672	-1.084 (-1.535; -0.633) [2]	
Resistance	4	-1.354	-2.48	-0.23	.018	87.859	-1.752 (-3.010; -0.499) [1]	
Mixed ^c	3	-0.430	-1.62	0.77	.481	94.350	Unchanged	
Group exercise ^b							2	
Yes	15	-0.985	-1.44	-0.53	<.001	84.222	Unchanged	
No	7	-0.743	-1.29	-0.19	.008	85.582	-1.175 (-1.926; -0.424) [2]	
Supervision ^b							, , , , , , , , , , , , , , , , , , ,	
Yes	19	-1.066	-1.48	-0.66	<.001	84.441	-1.333 (-1.807; -0.860) [3]	
No	3	-0.110	-0.33	0.11	.334	0.000	-0.078 (-0.265; 0.108) [2,	

							right of mean]				
Type of supervision ^b											
Exercise professional	10	-1.077	-1.64	-0.52	<.001	81.997	-1.450 (-2.037; -0.863) [3]				
Other professional/	4	-1.664	-2.88	-0.45	.007	87.977	Unchanged				
student											
Sample size											
intervention arm ^b											
n≥25	6	-0.444	-0.91	0.02	.061	86.212	-0.530 (-0.969; -0.090) [1]				
n<25	16	-1.144	-1.63	-0.66	<.001	82.403	-1.358 (-1.883; -0.834) [2]				
n≥10	16	-0.671	-1.02	-0.32	<.001	83.953	-0.809 (-1.172; -0.447) [2]				
n<10	6	-1.736	-2.70	-0.77	<.001	79.899	Unchanged				

Note. ^aIncluding 3 studies with MDD & Dysthymia. ^bData for a second intervention group within the same study were included for these analyses. ^cMixed exercise=aerobic and resistance exercise.

Supplementary Table 8. Meta Regression of Moderators/Correlates of Effects of Exercise on Depression for Studies with Low and Moderate Risk of Bias

Moderator	Number of RCTs	β	95%CI		p- value	R ^{2 c}
Main exercise response						
Mean age exercise	16	0.013	-0.01	0.04	.272	0.00
Mean age control	16	0.015	-0.01	0.04	.206	0.00
Duration of trial (in weeks) ^a	21	0.064	0.00	0.13	.039	0.12
Weekly frequency ^a	21	-0.005	-0.18	0.17	.954	0.00
Minutes per session ^a	19	-0.004	-0.02	0.02	.707	0.00
Sample size ^b	19	0.001	-0.00	0.00	.483	0.00
MDD (+ Dysthymia) only						
Mean age exercise	10	0.021	-0.00	0.04	.078	0.39
Mean age control	10	0.022	-0.00	0.05	.052	0.46
Duration of trial (in weeks) ^a	13	0.070	0.01	0.14	.034	0.26
Weekly frequency ^a	13	0.049	-0.15	0.24	.623	0.00
Minutes per session ^a	12	-0.021	-0.05	0.00	.095	0.26
Sample size ^b	11	0.002	-0.01	0.01	.614	0.00

Note. ^adata for a second intervention group within the same study were included for these analyses. ^bAverage sample size pre-post intervention. c R2 equal to R2 analog.

Supplementary Figure 1. Funnel Plot of Standard Error by SMD

